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ACA Anterior cerebral artery 
ADC Apparent diffusion coefficient 
aEEG Amplitude-integrated electroencephalogram 
AIS Acute ischemic stroke 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole receptors  
APC Antigen presenting cells 
BBB Blood-brain barrier 
CD Cluster of Differentiation 
CNS Central nervous system 
CPISR Canadian Pediatric Ischemic Stroke Registry 
CTL Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T lymphocyte antigen - 4 
CSF Cerebrospinal fluid 
CSVT cerebral sinus venous thrombosis 
DW MRI Diffusion-weighted magnetic resonance imaging 
EEG Electroencephalogram 
EPO Erythropoietin  
FOXP3 Forkhead box protein 3 
G-CSF Granulocyte colony-stimulating factor 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GM-IVH Germinal matrix - intraventricular hemorrhage 
HEV High endothelial venules 
HI Hypoxic-ischemic 
HIE Hypoxic ischemic encephalopathy 
IDO Indoleamine 2,3-dioxygenase 
IFN-γ Interferon - gamma 
IL Interleukin 
IVH Intraventricular hemorrhage 
KYN Kynurenine 
KYNA Kynurenic acid 
LPS Lipopolysaccharide 
MCA Middle cerebral artery 
MCP-1 Monocyte chemoattractant protein - 1 
MFI Mean fluorescence intensity 
DOI:10.14753/SE.2020.2341
6 
MHC Major histocompatibility complex 
MIP-1β Macrophage inflammatory protein - 1 beta 
MMP Matrix metalloproteinase 
MRI Magnetic resonance imaging 
MRS Magnetic resonance spectroscopy 
MSC mesenchymal stem cell 
NAIS Neonatal arterial ischemic stroke 
NE Neonatal encephalopathy 
NMDA N-methyl-D-aspartate 
NO Nitric oxide 
NOS Nitric oxide synthase 
PBMC Peripheral blood mononuclear cells 
PCA Posterior cerebral artery 
PET Positron emission tomography 
PVL Periventricular leukomalacia 
qPCR Quantitative polymerase chain reaction 
RAG1  Recombination activating gene 1 
RNS Reactive nitrogen species 
RORγt RAR-related orphan receptor gamma t 
ROS Reactive oxygen species 
S1P Sphingosine-1-phosphate 
S1PR Sphingosine-1-phosphate receptor 
SEP  Somatosensory evoked potential 
T-bet  T-box expressed in T cells 
TCR T cell receptor 
TGF-β Tumor growth factor - beta 
Th1 Helper T lymphocyte -1 
Th17 Helper T lymphocyte -17 
Th2 Helper T lymphocyte -2 
TNF-α Tumor necrosis factor - alpha 
Treg Regulatory T lymphocyte 
TRP  Tryptophan 
VCAM-1 Vascular cell adhesion molecule - 1 
VEP Visual evoked potential 
VLA-4 Very Late Antigen - 4 




Perinatal asphyxia and the consequent hypoxic-ischemic brain injury continues to 
be a major cause of perinatal morbidity and mortality and lifelong disability, despite 
the advances of the past decades in prenatal diagnostic methods and neonatal intensive 
care. It is important to note, that the initial degree of injury and the clinical status of 
the neonate often do not allow accurate prediction of the eventual neurodevelopmental 
outcome. While some children show favorable outcome and no significant disability, 
others develop severe neurodevelopmental impairments such as mental retardation, 
sensory impairment, cerebral palsy and seizures. Identifying factors which could 
differentiate between mild and severe outcome would be of great clinical value. 
It is becoming more and more clear, that the final outcome is influenced by several 
factors beyond the severity of the initial insult. One of the key factors determining the 
progress of brain injury is the neuroinflammatory response evoked by hypoxic-
ischemic injury. Neuroinflammation is now recognized to be a common feature of 
many neurological disorders, including hypoxic-ischemic brain injury. However, it 
appears to have dual aspects. While a certain level of inflammatory response is part of 
the physiological recovery process of the central nervous system, excessive 
neuroinflammation has been shown to play an important role in facilitating further 
brain injury. Emerging evidence indicates, that neuroinflammation could continue for 
many months after the initial brain injury and this latent phase could play an important 
role in the long-term consequences of perinatal hypoxic-ischemic brain injury.  
In the past decades important advances have been made in diagnosing perinatal 
hypoxic-ischemic brain injury. Introducing amplitude-integrated 
electroencephalogram monitoring into the routine clinical practice has enabled 
clinicians to follow the status of the neonate much more precisely. The widespread 
availability of MR imaging has opened new options for following the evolution of the 
brain injury and differentiating between asphyxia and disorders which are clinically 
overlapping, such as perinatal stroke. New MR modalities also allow earlier estimation 
of the injury with higher precision.  
Inarguably one the most important advancements of the past decade has been the 
introduction of therapeutic hypothermia into the common clinical routine, which has 
been shown to improve neurological outcome significantly. One of the fundamental 
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effects of hypothermia is the amelioration of the neuroinflammatory response and 
consequent tissue injury. Current research is focusing on developing novel 
immunomodulatory agents, many of which primarily target the neuroinflammatory 
response.  
The improving diagnostic possibilities in perinatal asphyxia also raised the 
awareness towards other etiologies of hypoxic-ischemic brain injury which are 
characteristic for the perinatal period. One of the most common is stroke, for which 
the neonatal period carries the highest risk in the entire childhood. Perinatal stroke is 
one of the most common causes of seizures, however it is seldomly diagnosed in a 
timely manner. The clinical presentation of the neonates often overlaps with global 
hypoxic-ischemic brain injury, and the real etiology is only later revealed upon MR 
examination. The pathophysiology of perinatal stroke is poorly understood; however 
it appears, that in-utero inflammation could be an important risk factor. Similarly to 
asphyxia, stroke also evokes a neuroinflammatory response, which plays an important 
role in the evolution of the brain injury. Disease specific preventive measures, 
prognostic factors and therapeutic strategies are not available, as neonates with stroke 
are not yet considered eligible for hypothermia therapy.  
Although recent years’ research has brought important aspects of the 
neuroinflammatory response to light, many questions remain. One area, where 
experimental data is especially scarce is the involvement of the adaptive immune 
system in neuroinflammation. Our research group has a longstanding interest in 
neonatal immune function and the role of human T cells in the pathophysiology of 
different diseases. T lymphocytes are key members of the adaptive immune system, 
exerting their effects largely via the cytokine network. In this study, we aimed to 
characterize the cytokine production of T lymphocytes. As previous studies have 
primarily focused on plasma cytokine levels, these data provide a novel insight into 
the function of T cells after perinatal hypoxic-ischemic brain injury. We also aimed to 
learn more about the latent phase of neuroinflammation to identify players of the 
inflammatory network, which could be responsible for this prolonged immune 
response. We therefore extended our study period to the entire first month of life.  
By joining this research group in 2010, I have had the opportunity to rely on its 
long experience in the field of perinatal immunology and flow cytometry and carry out 
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the measurements which provide the basis of this thesis. We hope that the results from 
our work could improve our understanding of the characteristics of this critical period 
of life and hopefully support the search for prognostic and therapeutic targets, which 
could open the opportunity for individualized care in the future. 
2.1 THE NEONATAL BRAIN  
- SELECTIVE VULNERABILITY OR FUNCTIONAL 
PLASTICITY AFTER HYPOXIA-ISCHEMIA? 
The human brain has a high requirement of oxygen and glucose, but lacks 
energy and nutrient reserves, and thus is highly dependent on a continuous blood flow 
(1). The hypoxic-ischemic (HI) injury of the developing brain is one of the leading 
causes of child mortality, morbidity and long-term disability (2). The developing fetal 
and neonatal brain responds very differently to HI injury than the mature adult brain. 
On the one hand, neonatal brain is able to withstand much longer periods of 
hypoxemia, than the adult brain (3). This is due to a number of adaptive mechanisms, 
such as the capacity to increase cerebral blood flow (4). On the other hand, severe 
hypoxia together with ischemia can initiate a self-sustaining cascade of neurotoxic 
events, which can last for weeks and result in delayed brain damage (5, 4, 6, 7). In the 
immature brain, the development of central motor pathways can be disturbed, and 
developmental plasticity can be altered (2). Certain cerebral regions of the developing 
brain are especially susceptible to HI injury, and these change as the fetus matures (8, 
9). As our understanding of the characteristics of CNS development deepened, many 
circumstances have been revealed, which may be responsible for this increased 
vulnerability of the developing brain to hypoxia-ischemia (1). The most important 
factors determining the severity and type of perinatal HI injury are  
1) The intensity and timing of HI injury in relation to birth  
2) The degree of maturation of the CNS at the time of insult 
3) The selective ischemic vulnerability 




Gestational age has a determinate impact on the characteristics of HI injury. 
For instance, preterm infants are much more resilient to hypoxemia than near-term 
infants. Premature fetal sheep can tolerate up to 25 minutes of complete cessation of 
blood flow, whereas in near-term fetuses the tolerable time of hypoxia is maximum 10 
minutes (10, 11) This is most likely due to the gradual increase in the metabolic rate 
of the CNS as the fetus matures (8). Term neonates are also much more likely respond 
to severe HI injury with blood-brain barrier (BBB) breakdown, significant brain 
oedema and massive neuroinflammatory response causing the impairment of CNS 
metabolism, excitotoxicity, free radical production and high levels of apoptosis (8, 12-
14). 
Global hypoxia-ischemia most often damages specific structural groups (4, 15, 
16). Gestational age and the level of CNS maturity determine the characteristics of the 
HI lesions and the associated clinical patterns of disability. The lack of cerebral 
circulatory autoregulation and the presence of fragile, poorly anastomosed blood 
vessels in the germinal matrix (17, 18) put preterm neonates at extremely high risk for 
germinal matrix - intraventricular hemorrhage (GM-IVH), one of the most devastating 
forms of permanent perinatal injury (Figure 1).  
Figure 1. MRI image showing a characteristic injury of the premature brain, 
germinal matrix - intraventricular hemorrhage on both sides with parenchymal 
involvement on the right (arrows). A) Sagittal and (B) coronal T2 weighted FSE 




Figure 2. MRI image showing a characteristic form of injury of the premature brain, 
periventricular leukomalacia (PVL). Image was published by Counsell et al. (19), 
with the following figure legend: PVL in an infant at 28 weeks gestational age. (A) 
Transverse T1 weighted image at the mid-ventricular level showing cystic PVL as 
areas of low signal within the cerebral white matter posterior and anterior to the 
lateral ventricles (arrows). (B) Transverse T2 weighted FSE image at the mid-
ventricular level showing the cystic lesions as high signal intensity (arrows). (C) DWI 
image showing areas of restricted diffusion around the lateral ventricles as high signal 
intensity (arrows). (D) T2 weighted FSE image of the same infant at 40 weeks GA 
showing squared off posterior horns of the lateral ventricles (arrows) and diminished 
white matter posteriorly. Cystic lesions are shown anterior to the anterior horns of the 
lateral ventricles (arrowheads) 
DOI:10.14753/SE.2020.2341
12 
Until the 32nd week of fetal development, the selective vulnerability of late 
oligodendrocyte progenitors (20) make the periventricular white matter especially 
susceptible to damage, making periventricular leukomalacia (PVL) (Figure 2), often 
associated with spastic palsy, the other common form of injury in preterm neonates 
(4). The consequent motor, sensory and cognitive deficits show specific patterns 
characteristic for preterm brain injury, for example cortical visual impairment (2). 
Term neonates on the other hand, respond with different patterns of injury to 
severe or “near-total asphyxia”. Based on magnetic resonance imaging (MRI), the 
most common types of damage are parasagittal cortical injury and the symmetric 
injury of basal ganglia, the thalamus, hippocampus and the peri-Rolandic cerebral 
cortex (21-26), often along with brain stem injury (Figure 3). The fragility of vessels 
decreases by this time and if IVH is present, it usually is associated to thalamic 
bleeding (13). Periventricular white matter damage is also uncommon, although 
transient MRI-signal alterations often show the involvement of the posterior internal 
capsule (25, 27). The associated clinical symptoms in term neonates are severe, 
permanent motor impairment with rigidity, which affects the upper extremities more 
than the lower ones and motor speech impairment (22, 4, 24). One factor, which can 
influence the gestation-age dependent pattern of HI injury is the localization of the 
“watershed” boundary zones, which changes as the vascularization of the fetal brain 
evolves (8). In term infants these lie between the major cerebral arteries and overlap 
with the structures most affected by HI. Although cerebrovascular factors might have 
an impact on the initial HI insult, it appears, that the endogenous vulnerability of 
certain structures in the developing brain might play a much more important role in 
determining the final pattern of injury and disability (4). 
The selective vulnerability of the developing brain to hypoxic-ischemic injury 
has been the focus of intensive research for decades, however, many questions remain. 
One working model proposes, that the key to understanding selective neuronal 
vulnerability in term infants lies in the position of the vulnerable structures within the 
maturing excitatory neuronal circuits (28). It suggests, that excitotoxicity, which is 
the selective death of neurons and glia due to the overstimulation of excitatory 
neurotransmitter - mainly glutamate – receptors, is one of the key processes in the 
pathological development of HIE. In fact, every vulnerable region in term neonates 
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(the thalamus, putamen and peri-Rolandic cortex) receives major excitatory 
glutamatergic input (29). 
 
Figure 3. MRI images comparing the brain of a healthy term neonate with three 
term neonates with HIE. This image was published by Rutherford et al. (30) with 
the following legend: the posterior limb of the internal capsule. T1 weighted images 
(top row) with T2 weighted images (bottom row). (a) Normal appearances of the 
posterior limb of the internal capsule (arrows). (b, c, d) Abnormal appearances of 
paired T1 and T2 weighted sequences in three different infants with HIE.  
Authors hypothesize, that these circuits become hyperactivated and the 
synapses are flooded with glutamate, causing excitotoxicity, which triggers 
selective neuronal death (4, 31, 32, 6). This model also explains why structures such 
as the internal and external segments of the globus pallidus are spared during HIE, 
but not in other disorders, such as kernicterus (28), since they are strongly inhibited 
during the hyperactivation of these circuits (22). Furthermore, the inhibition of the 
globus pallidus, alleviates the inhibition of the thalamus, which leads to enhanced 
cortical stimulation. This is consistent with the clinical signs of HIE, which indicate 
cortical hyperactivity, such as seizures and abnormal electroencephalographic 
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(EEG) background activity (3, 6, 33). Further evidence suggests, that vulnerable 
regions show selective glucose hypermetabolism (6), which appears to reflect 
enhanced glutamate release and reuptake at the hyperactive excitatory synapses (34) 
and correlate with outcome (35).  
Oxidative stress appears to be the other major cause of neuronal damage 
following perinatal HI injury by triggering apoptosis via the mitochondria along other 
effects (36). Oxidative stress emerges due to the imbalance between the production 
and neutralization of free radicals, such as reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) (8). The developing brain is highly vulnerable to oxidative 
stress, much more than the adult brain due to its higher lipid content (37), the uniquely 
high levels of polyunsaturated fatty acids, its high oxygen requirement and thus, 
increased ROS-generating capacity, the low concentrations and activity of antioxidants 
and the higher levels of redox-active iron (38-43).  
Nitric oxide (NO), although an important physiological mediator (44), when 
produced in excess amounts, has neurotoxic effects via the generation of RNS, such as 
peroxynitrite (OONO) (45). RNS-mediated damage includes lipid peroxidation, 
impairment of mitochondrial respiration and the induction of ROS production (46-48). 
The nitric oxide synthase (NOS) enzyme has three major isoforms: the neuronal NOS 
(nNOS), the endothelial NOS (eNOS), and the inducible NOS (iNOS), which is mainly 
found in activated inflammatory cells (8, 49). Increased NO production in specific 
cerebral regions appears to be an important component of selective ischemic 
vulnerability (50). Cells expressing the immature form of N-methyl-D-aspartate 
(NMDA) glutamate receptor are generally highly resistant to HI injury and NMDA 
mediated excitotoxicity (51, 52) and are abundant in regions, which are known to be 
selectively vulnerable to HI, such as the basal ganglia and thalamus (53). Increased 
stimulation after HI injury via this NMDA receptor leads to robust NO production due 
to the up-regulation of nNOS (54). Both the elimination of these neurons and the 
inhibition of NMDA coupling lead to the amelioration of ischemic injury 
(55).  Furthermore, nNOS knockout in mice proved to be highly neuroprotective (56, 
57). The inhibition of nNOS and iNOS also improved long-term functional outcome 
(58). Overall, it appears, that excitotoxicity and oxidative stress are the two most 
important mediators of perinatal HI brain damage and are key to understanding 
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selective ischemic vulnerability (8, 50). 
Another important characteristic of the immature brain is, that neurons are 
much more prone to undergo apoptosis than in the adult brain, as programmed cell 
death is an important mechanism for refining newly formed neuronal pathways in 
the developing brain (59, 50, 60, 61). Compared with adult acute ischemic stroke 
(AIS), the ratio of apoptotic vs necrotic cells is much higher in the basal ganglia and 
cerebral cortex of term neonates one week after HI injury (62, 4, 63). This suggests, 
that apoptosis is a key step in the pathomechanism of HI brain injury, as is indicated 
by the elevated level of death-receptor proteins in the  brain and cerebrospinal fluid 
(CSF) of neonates after HI brain injury (64, 65).  
There is clear evidence from imaging studies and animal models, that the HI 
injury in the neonatal brain evolves in the first days to weeks after the initial insult 
(66) and the majority of the cell loss happens as a consequence of the ensuing 
neuroimmune response (67-69). The release of excitatory and inflammatory signals 
promotes robust microglial activation, initiating leukocyte migration to the CNS, 
which in return induce further inflammation. This cascade of events known as 
neuroinflammation, leads to the release of a wide range of inflammatory mediators, 
increased excitotoxicity and oxidative stress and the further destruction of the BBB 
(8). These processes all lead to accelerated cell death in the immature brain via 
apoptosis or necrosis (50). The growing understanding of the selective ischemic 
vulnerability of the developing brain has also opened the chance for new 
immunomodulatory therapeutic approaches in the form of NMDA antagonists 
combined with caspase inhibitors, which could yield an enhanced neuroprotective 
effect by inhibiting excitotoxicity and apoptosis at the same time (4, 70, 71).  
Along the increased vulnerability, it is also important to consider, that the 
neonatal brain has a remarkable ability to recover and remodel after HI injury, due to 
its high level of neuroplasticity. Synaptic organization and the development of white 
matter pathways continues for years after birth (72, 73). One of the most relevant of 
these processes, is the activity-dependent plasticity of the descending motor pathways, 
which can influence outcome after unilateral hypoxic brain injury (74). Therefore, 
there is intensive research regarding neurodevelopmental techniques, which could 
alter this process in a favorable manner (74). Several animal models have confirmed, 
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that normal corticospinal tract connectivity and motor cortical map can be re-
established, and motor function can be improved (75, 76) with electrical stimulation 
and/or targeted physiotherapeutic training.  
It appears, that the neurogenesis capacity of the developing brain is not 
damaged by HI, in fact, in vivo data shows, that neural stem cell proliferation increases 
in the subventricular zone after HI in mice (77, 78). Evidence also indicates, that 
compared to the mature, adult brain, where remodeling is very limited, the developing 
brain has great capacity to modify its structure and function to overcome functional 
loss after HI injury (79, 80, 73). The developing brain retains its ability to “recruit new 
areas and form new circuits by reorganizing the neural network” (81, 82). Jung et al. 
utilized novel MR imaging techniques to demonstrate neuroplasticity on many levels, 
from cellular to systemic changes, such as cortical remapping during the spontaneous 
functional recovery of mice who sustained neonatal HI injury.  They found, that the 
contralesional hemisphere was able to take over the governing of the motor function 
of both sides, which authors interpret as “spontaneously generated active plasticity 
with brain laterality established autonomously via the modification of neural 
circuitry”. This process was associated with the recovery of motor functions (73). 
However, it is important to distinguish “good plasticity” from “bad plasticity”. As an 
example, excessive stimulation of developing neuronal circuits due to HI injury and 
subsequent seizures, can lead to altered signaling and neurotransmission, wrong 
targeted innervation and the interruption of developmental apoptosis. This could result 
in abnormal neural circuitry, which contribute to epilepsy, motor and cognitive 
impairment (83, 84). 
In conclusion, although, a growing body of evidence supports the higher 
neuroplasticity of the developing brain compared to the adult brain, it still appears, that 
the immature brain sustains far worse neurodevelopmental outcomes following severe 
ischemic injury (2). This indicates, that the crucial vulnerabilities of the developing 





2.2 PERINATAL ASPHYXIA 
2.2.1 DEFINITION AND INCIDENCE 
Several terms are often used as synonyms to describe the clinical syndrome, 
which evolves in the days following HI injury in neonates such as hypoxic-ischemic 
encephalopathy (HIE), neonatal encephalopathy (NE), perinatal asphyxia and birth 
asphyxia (85). As per the definition of Nelson and Leviton, NE is a “clinically defined 
syndrome of disturbed neurologic function in the earliest days of life in the term infant, 
manifested by difficulty with initiating and maintaining respiration, depression of tone 
and reflexes, subnormal level of consciousness, and often by seizures”. This definition 
does not however specify etiological cause, and in fact, not all neonates who present 
with NE have an obvious history of perinatal hypoxic-ischemic episode (86). 
According to the definition of Volpe, hypoxemia is the “diminished amount of oxygen 
in the blood supply”, whereas cerebral ischemia is the “diminished amount of blood 
perfusing the brain”. As detailed previously, evidence shows, that the latter has greater 
impact in neonates, as glucose is also deprived from the developing brain along with 
oxygen, contributing to the primary energy failure (85, 87).  The term asphyxia in 
addition refers to the “impairment of the exchange of blood gases oxygen and carbon 
dioxide”, which occurs in the fetus if the umbilical or placental perfusion is 
compromised (85). To try to maintain a temporary homeostasis, the fetal circulation 
becomes rearranged, reducing nonobligatory energy consumption and increasing the 
blood flow of the brain, heart and adrenal glands. However, glucose reserves are 
rapidly consumed, leading to anaerobic metabolism and severe metabolic acidosis, due 
to lactate accumulation (2). In the clinical practice, indirect markers are used to 
estimate the degree of hypoxia-ischemia, such as low Apgar scores, decreased 
peripheral blood pH and acid-base parameters indicating metabolic acidosis. If these 
alterations are present along with the signs of encephalopathy (altered state of 
consciousness, hypotonia, abnormal reflexes, clinical seizures (88)), the diagnosis of 
hypoxic-ischemic encephalopathy can be established (85). Although there is a 
significant overlap in the above definitions, for the sake of clarity, the terms perinatal 




The incidence of HIE ranges between 1.0 and 8.0 per 1000 live births 
worldwide, with higher percentages in the developing world (85).  In the developed 
world, the incidence of neonatal encephalopathy (NE) is between 2.5 and 3.5 per 1000 
live births with a combined point estimate of 3.0 per 1000 live births, while the 
incidence of HIE is estimated to be between 1.3 and 1.7 per 1000 live births with a 
combined point estimate of 1.5 per 1000 live births. (85).  
Perinatal asphyxia continues to be a major cause of perinatal mortality and 
long-term disability, despite the advances in neonatal healthcare and the introduction 
of therapeutic hypothermia as part of standard care (2). Perinatal asphyxia is 
accountable for approximately one million  (23% of all) neonatal deaths worldwide 
(89). In the developed world, at least 0.5% of term neonates required resuscitation after 
birth due to a 5-min Apgar score of 6 or less (90), and in 2013 in the Netherlands at 
least 0.2% of all term neonates were severely depressed with a 5-min Apgar score of 
3 or less. Among the latter group mortality was 24% (91). 
Even though some surviving children show favorable neurological outcome, 
many sustain neurodevelopmental disabilities ranging from fine motor impairments 
and developmental delay to severe hindrances such as mental retardation, sensory 
impairment, cerebral palsy and epilepsy (92). Data indicates, that despite the 
significant reduction of perinatal morbidity in the developed world, the incidence of 
cerebral palsy has remained almost the same in the past 40 years  (8, 93). The degree 
of individual variability in neurological outcome after perinatal asphyxia is especially 
intriguing, since it shows little correlation with the initial clinical status. It is thus 
crucial to constantly improve our understanding of the pathophysiology of HIE, since 
the key pathological factors regarding outcome are likely to be part of the 




2.2.2 RISK FACTORS 
Several studies aimed to identify the potential risk factors of HIE, however, 
there was a high level of variability between the studies. In an Italian case-controlled 
study, out of the included 30,580 infants, 27 (0.09%) developed NE. In 26% of the 
cases only antepartum risk factors were present, in 22% only intrapartum risk factors 
could be identified, including acute intrapartum events, whereas in 44% of the cases 
both antenatal and peripartum risk factors were present. In 2 cases (7%) however, no 
risk factors could be identified (94). In the largest case-controlled study performed in 
Western Australia, in 69% of cases only antepartum risk factors were present, whereas 
only intrapartum risk factors could be identified in just 4% of the cases. In 22% of 
cases both were present, and in 2% no risk factors could be identified. There is also 
much discussion regarding the timing of the HI insult, however, prospective MRI 
based studies indicate, that the majority of HI injury is likely to occur at or close to the 
time of birth (95). 
Several risk factors of NE have been identified, many of which are common in 
developed and developing countries. Identifying modifiable risk factors is a key point 
in current research. Risk factors, which have been shown to be associated with 
perinatal HIE are shown in Table 1. The presented information has been collected from 
the two largest case-controlled studies, one from Western Australia and the other from 
Nepal. Interestingly, there is a considerable overlap in the risk factors, despite the 
major differences in the socioeconomic background of the patients in the two studies. 
Antepartum maternal risk factors include older maternal age, hypertension, 
thyroid disease, infertility treatments, severe pre-eclampsia and several 
sociodemographic factors (employment, insurance, etc.). Intrapartum complications 
such as cord abnormalities, maternal fever or prolonged membrane rupture to delivery 
interval resulted in a non-significant increase in the risk of NE in the Western 
Australian study. Non-cephalic presentation, forceps delivery, emergency section and 
catastrophic intrapartum events such as placental abruption or uterine rupture were 
associated with HIE (96, 97, 50, 85).  
Of the fetal risk factors the most common were growth restriction in Western 
Australia and twin pregnancy in Nepal. Risk factors also included fetal distress and 
meconium stained amniotic fluid, however these are also the consequences of 
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intrauterine hypoxia and thus cannot be considered independent risk factors (96, 97, 
85). Postnatal complications were present in less than 10% of cases and were severe 
respiratory distress, shock and sepsis (50).  
Table 1. Summary of the risk factors of neonatal encephalopathy (NE). The data 
were collected from the two largest case-control studies. 1 significant risk factor in 
Western Australian study, 2 significant risk factor in Nepal study (98, 96, 97). 
Maternal risk factors Fetal risk factors 
Antepartum 
Higher maternal age1,2  Gestational age > 41 weeks1 
Primiparity2 Intrauterine growth restriction1 
Family history of seizures  
and neurological disorders1 
Abnormal placenta1 
Twin pregnancy2 









Lack of antenatal care1,2 
Sociodemographic factors1  
Intrapartum 
Pyrexia1 Non-cephalic presentation2 
Prolonged interval from rupture 
of membranes to delivery1,2 
Persistent occipitoposterior 
presentation1 
Abnormalities in blood pressure1 Nuchal cord1, cord prolapse1,2 
Instrumental delivery1,2 Shoulder dystocia1 
Emergency section1,2 Fetal distress1 
Induced delivery2 Meconium stained amniotic 




Perinatal asphyxia evokes the injury of the central nervous system (CNS) due 
to the severe lack of oxygen and perfusion, leading to hypoxic-ischemic brain injury. 
In the initial phase, due to circulatory redistribution, a temporary compensation can be 
maintained, where nonobligatory energy consumption is minimized, cerebral blood 
flow is increased regionally, and neuronal activity is suppressed (99, 100, 2, 101). After 
a while cerebral blood flow gradually decreases due to either regional vasoconstriction 
or the progressive collapse of cardiac output (8, 102, 100). This leads to reduced 
oxygen delivery, decreased oxidative phosphorylation causing the depletion of high 
energy phosphate compounds (i.e. ATP), the rapid consumption of glucose reserves, 
and severe lactate acidosis, as a result of anaerobic metabolism (103-105, 2). This 
primary energy failure damages the BBB, leads to cerebral edema and initiates 
excitotoxicity and oxidative stress, culminating in the first wave of necrotic and 
apoptotic cell death. (8, 106, 107, 14).  
If neonatal resuscitation is successful, glucose and ATP reserves are 
temporarily restored. However, this recovery phase is followed by the second wave of 
energy failure within 6 hours, as the HI brain injury continues to develop over the next 
weeks (2, 108, 6). The main features of the second phase are the secondary energy 
failure, characterized by an even more pronounced exhaustion of cellular ATP stores, 
further increase in lactate levels and pH alterations (109, 110, 2), the robust 
neuroinflammatory response and the decrease of cerebral autoregulation (8, 111, 112, 
40). ATP deprivation combined with lactate acidosis leads to the failure of active 
membrane transport, leading to intracellular accumulation of Na+, Ca2+, and Cl− ions. 
Consequently, prolonged neuronal membrane depolarization occurs, leading to 
excessive presynaptic glutamate release (113). In the absence of ATP and glucose, the 
function of glutamate reuptake pumps on perisynaptic glial cells is compromised (4, 
34), leading to the accumulation of extracellular glutamate and other excitatory 
neurotransmitters, which causes the overstimulation of ionotropic glutamate receptors 
such as NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptors (40). 
This leads to excessive calcium influx, initiating the excito-oxidative cascade. 
Intracellular calcium overload activates lipases, proteases and endonucleases, leading 
to the degradation of the cytoskeleton, mitochondria dysfunction, the swelling of the 
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cell and eventually apoptosis or necrosis (8, 4, 114, 2). Membrane depolarization and 
excessive excitatory stimulation can also induce seizures (115). Since glutamate 
receptors are vital regulators of the fetal brain development, they are expressed 
abundantly, therefore severe fluctuations in excitatory input have massive detrimental 
consequences (116, 40). The neuroinflammatory response is interconnected with this 
vicious circle in many ways. The activation and invasion of inflammatory cells results 
in the robust release of cytokines and other mediators, which continue to exacerbate 
the excito-oxidative cascade (8, 40) (Figure 4). In light of the above, it is not very 
surprising, that the majority of accelerated cell death happens during this second phase, 
where most of the free radicals, inflammatory mediators and excitatory amino acids 
are released (67, 68, 2, 69). 
 
 
Figure 4. Key features of the neuroinflammatory response 
This image was originally published by Sajja et al. in Frontiers (117) illustrating the 
contribution of glial cells to secondary brain injury.  
Following the initial few days, the tertiary phase of the HI brain injury begins, 
which can continue for weeks after the initial insult. The primary mediators of this 
phase are the activated inflammatory cells and depending on the local homeostasis 
created by the neuroinflammatory response, the excito-oxidative injury can be 
sustained, and repair mechanisms can be stalled (118).  The neuroinflammatory 
response is a complex process, which may have dual aspects being a hindrance, but 
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also a significant help in the recovery of the CNS. The substantial variability in 
outcome is likely related to the characteristics of the individual response to the initial 
HI insult, therefore understanding its characteristics is the primary aim of current 
research in the field. The neuroinflammatory response will be discussed in detail in 
Chapter 2.4.  
2.2.4 CLINICAL PRESENTATION 
Evidence indicates, that the majority of HI injuries happens during or in close 
proximity to birth (119). Term neonates generally present with symptoms of perinatal 
asphyxia directly after birth. The first mode of assessment is the Apgar score (120, 91), 
which is an evaluation of the cardiac, pulmonary and neurological status of the neonate 
at 1, 5 and 10 minutes after birth. The consequences of a severe HI insult are often 
already present at birth, indicated by a 5-min Apgar score under 5. Further signs of 
severe asphyxia include acidosis within 60 minutes of birth indicated by “umbilical-
cord, arterial, or capillary pH of <7.00 or base deficit of ≥16 mmol per liter, signs of 
moderate-to-severe encephalopathy (lethargy, stupor, or coma), abnormal tone (focal 
or general hypotonia or flaccidity), abnormal reflexes (absent or weak suck or Moro 
response, sometimes oculomotor or pupillary abnormalities) and clinical seizures” 
(121). 
Symptoms usually evolve during the first days of life and their severity and 
persistence is in correlation with the severity and duration of the HI insult (50, 91, 122, 
6). Based on the clinical presentation, HIE can be classified as mild, moderate or 
severe (Table 2). Mild HI insult might manifest in subtle neurological abnormalities 
(such as transient drowsiness) without multi-organ damage, whereas a severe insult 
usually leads to moderate-to-severe HIE and variable degree of multi-organ failure 
(91, 123).   
During the first 12-24 hours neonates with mild HIE generally show some 
neurological alterations, such as restlessness, moderate hypertonia, often associated 
with periodic breathing and feeding difficulty, which are likely associated with 
“abnormal stimulation or transient malfunction of the brain” (91). The most common 
systemic symptom is decreased urinary output. After 24 hours neonates with mild-to-
moderate HIE can improve in their overall clinical and neurological status. They often 
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reach normal level of consciousness and begin to tolerate feeds during the first week 
of life. Laboratory parameters usually show a similar tendency (91). 
Neonates with moderate-to-severe HIE on the other hand often show more 
profound neurological alterations during the first days, such as “depressed state of 
consciousness, gazing with abnormal papillary size, hypotonia, periodic breathing 
with apnea, bradycardia, and signs of seizure activity” (50, 91). In the most severe 
cases, neonates are often lethargic, and stupor and early onset, overt seizure activity is 
also common (91). In term infants, seizures are usually multifocal and clonic and can 
manifest in apneic spells (91). Systemic symptoms almost always include kidney 
damage and respiratory insufficiency with prolonged apnea, which often makes 
mechanic ventilation necessary around 48-72 h of life. HI injury can cause 
cardiomyopathy, with the need for inotropes, the severity of which is in close relations 
with the severity of the HI insult (124). As the HIE progresses, after 24 hours either a 
gradual stabilization or deterioration can be observed. In the first case, a gradual 
stabilization of physical parameters and improvement of alertness level occurs, 
however, neurological abnormalities, such as “hypo- or hypertonia (in the case of basal 
ganglia damage), feeding difficulties, decreased suck, abnormal swallow” likely reside 
(91). Hypotonia and proximal limb, facial and bulbar muscle weakness with amplified 
reflexes can persist for months after HI brain injury (50). In the second case, a gradual 
deterioration occurs, most likely as a consequence of the secondary phase of HI injury 
and neuroinflammation (109, 68). Seizures often become refractory, indicated by 
“apneic episodes, shrill cry, and jitteriness” (50). Neonates’ consciousness level 
progressively deteriorates, as brain stem functions start to be affected, and mechanic 
ventilation is almost always inevitable. Responsiveness decreases, seizure activity 
increases, and pupils become dilated (91). In the most severe cases, neonates die within 
the first week of life. Autopsy-based studies revealed cytotoxic brain edema and 





2.2.5.1 CLINICAL STAGING 
Prenatal diagnostic methods (such as fetal heart rate patterns, scalp blood gas, 
meconium passing) may indicate fetal distress, however, they are poor predictors of 
the development of HIE and of long term neurological outcome (91, 126). The Apgar 
score is a somewhat better tool for direct postnatal assessment, however it is still far 
from reliable. A 10 min Apgar score of 5 or less predicts perinatal HI with 43% 
sensitivity and 95% specificity (127). However, HI injury cannot be ruled out in 
neonates with a good Apgar score (91), as 1 min Apgar score of 3 or less was found in 
only 31% of neonates with HIE (128). 
The clinical features of the first few days show better correlation with future 
neurodevelopmental outcome, therefore, the need for clinical staging became evident. 
The first clinical staging system of HIE was established by Sarnat and Sarnat in 1976, 
it defines 3 stages of HIE based on neurological status and EEG characteristics of 
affected neonates (91, 6). This scoring system was then modified by Fenichel in 1983, 
to define mild, moderate and severe HIE, by including only clinical features (129) 
(Table 2). The latter system became the standard mode of clinical staging of HIE in 
neonates in the past decades worldwide, however, neurodevelopmental outcome 
cannot be reliably predicted based on solely the clinical severity of HIE.  
In the “TOBY (TOtal Body hYpothermia) - Whole body hypothermia for the 
treatment of perinatal asphyxial encephalopathy trial”, term neonates with moderate-
to-severe perinatal asphyxia were selected for total-body moderate hypothermia, 
initiated within 6 hours of birth and continued for the first 72 hours of life (121). They 
established the inclusion criteria to identify clinical features indicative of a developing 
encephalopathy early on (88). A modified version of this criteria system is used in the 





Table 2. Clinical staging of hypoxic-ischemic encephalopathy according to Sarnat 
and Sarnat (6) and Fenichel (129) This table is based on the publication of 
Groenendaal et al. (91) 
 Stage 1 Stage 2 Stage 3 





Neuromuscular control Normal Mild hypotonia Flaccid 
Suck / Moro reflex Normal Weak Absent 
Oculo-vestibular / tonic 
neck reflex 







Seizures None (Multi)focal Decerebrated 
EEG findings Normal 
Low voltage  
(δ/0 waves) 
Isoelectric 
Duration < 24 h 2-14 days Hours to weeks 
 
 Mild Moderate Severe 
B) Fenichel 
Consciousness Irritable/hyperalert Lethargic Comatose 





Suck reflex Abnormal Poor Absent 
Primitive reflexes Exaggerated Depressed Absent 
Seizures Absent Present Present 












The following criteria are used to select neonates eligible for therapeutic hypothermia. 
Neonates meeting both criteria A and B may be considered for treatment with cooling. 
A) Infants ≥36 completed weeks gestation admitted to the neonatal unit  
with at least one of the following: 
Apgar score of ≤ 5 at 10 minutes after birth 
Continued need for resuscitation, including endotracheal or mask 
ventilation, at 10 minutes after birth 
Acidosis within 60 minutes of birth (defined as any occurrence of umbilical 
cord, arterial or capillary pH < 7.00) 
Base Deficit ≥ 16 mmol/L in umbilical cord or any blood sample (arterial, 
venous or capillary) within 60 minutes of birth 
B) Seizures or moderate to severe encephalopathy, consisting of: 
Altered state of consciousness (reduced response to stimulation or absent 
response to stimulation) AND 
Abnormal tone (focal or general hypotonia, or flaccid) AND 
Abnormal primitive reflexes (weak or absent suck or Moro response) 
 
2.2.5.2 NEUROPHYSIOLOGY 
The assessment of neonates’ brain activity by EEG has become an important 
tool in clinical staging, evaluating eligibility for therapies such as hypothermia, and 
predicting outcome (130, 131, 91, 132-134). Since the characteristics of the 
background activity in the first few days of life appear to be more important than those 
of the seizure activity, conventional multi-channel EEG recordings have limited value, 
as they give a detailed overview of a short time period (30-45 minutes) (135). In 
clinical practice, the usage of a simplified method, the amplitude-integrated EEG 
(aEEG) has become widespread, as it is easy to apply, correlates well with 
conventional EEG data and allows a continuous monitoring of brain activity in the first 
days of life (91, 136). Data from aEEG monitoring has predictive value, especially of 
severe injury, as suppressed background activity after 24 hours, or flat or continuous 
low voltage in the first 6 hours was almost always associated with poor outcome (137, 
91, 138, 139). However, in neonates, where the background activity becomes normal 
within 24 hours, 39% still developed some neurological disability later on (139). On 
the other hand, continuous normal background activity was associated with normal 
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outcome (91, 138). Evoked potentials (EP) are electrical responses to repetitive visual, 
auditory or somatosensory stimulation, which can be assessed on the EEG. Visual and 
somatosensory evoked potentials in the first week of life (VEP and SEP respectively) 
also correlate with outcome, however, their clinical use is much less common than that 
of the aEEG (137, 91). 
2.2.5.3 NEUROIMAGING 
Although cranial ultrasound has been used for many years and is a good tool 
for bedside monitoring, its sensitivity after perinatal HI injury is far exceeded by 
magnetic resonance techniques (91). In the past decades, cranial magnetic resonance 
imaging (MRI) has become the standard diagnostic method following perinatal HI 
injury (95, 140) (Figure 5). MRI is the most informative, when performed between 4-
7 days of life, as HI brain lesions acquired in the perinatal period are the most likely 
to be visible at this time period (141, 91). Following perinatal HI, the classical pattern 
of injury on MRI images is abnormalities in the thalamus and basal ganglia, and the 
surrounding white matter in the most severe cases (91, 142). Specific modalities, such 
as diffusion-weighted (DW) MRI are highly sensitive to early changes elicited by HI 
injury, especially if cranial mapping is performed by calculating the apparent diffusion 
coefficient (ADC) of water, based on which early cytotoxic edema can be 
differentiated from vasogenic edema (91, 143). Although DWI is a sensitive mode of 
evaluating the ischemic injury in the early phase, it often underestimates the final 
extent of damage, especially in the basal ganglia and thalamus (30).  
Cranial magnetic resonance spectroscopy (MRS) can also be a valuable tool, 
as it provides insight into the metabolic changes of the CNS following perinatal HI. 
Poor neurological outcome was associated with elevated lactate level in the basal 
ganglia and thalamus of neonates on 1H-MRS (144). Lower levels of phosphocreatine 





Figure 5. Different MRI modalities for assessing perinatal HIE. This image was 
published by Rutherford et al. (30) with the following legend: Diffusion-weighted 
imaging in the basal ganglia and thalami. Top row. T1 (left) and T2 (middle) weighted 
images and ADC map (right) acquired on day 3. The ADC map shows several regions 
of abnormal low signal intensity within the basal ganglia and thalami (BGT) that look 
relatively subtle (circular region of interest). Bottom row. Day 22. T1 (left) and T2 
(right) weighted images. The BGT abnormalities are very severe with no normal 
looking tissue within the BGT (circular region of interest). Any abnormality within the 
BGT on an early ADC map is likely to be clinically significant and any one diffusion-
weighted examination is likely to underestimate the final lesion load. By day 22 the 
white matter signal intensity (arrow) has become abnormally high and there has been 






Neonates born with poor Apgar score due to perinatal asphyxia often require 
perinatal resuscitation and subsequent intensive supportive care in the first weeks of 
life. The most important aspects of supportive care are adequate ventilation and 
oxygenation, correction of acid-base status, cardiac support, anti-convulsive treatment, 
the maintenance of normal blood glucose and electrolyte levels, and the management 
of blood count abnormalities (145, 146). Hypoxia (91) and hyperoxia(147), 
hypocapnia (148), hyperglycemia (149), hypotension and hypoperfusion (124), 
metabolic acidosis, and seizures (150) have all been documented to aggravate perinatal 
HI brain injury (146, 91). Therefore, careful management of these parameters is 
essential in the first week after perinatal asphyxia. In the first 48 h of life enteral 
feedings should be withheld due to an increased risk of necrotizing enterocolitis, 
however, sufficient caloric intake should be established as soon as possible (151, 91). 
Research data indicates, that the most critical time window for neuroprotective 
intervention is the first 6 hours after birth, as this is likely the time between the initial 
HI insult and resuscitation and the secondary brain damage (146, 152). In the current 
clinical practice, hypothermia is the only neuroprotective treatment, which specifically 
targets the consequences of HI brain injury and has been proven to be beneficial in 
large clinical trials (146). Following the TOBY trial, published in 2014, hypothermia 
has become the standard of care for term neonates with perinatal asphyxia and 
consequent HIE. Authors found, that total body moderate hypothermia, did not alter 
combined rates of death and severe disability, but improved neurological outcome in 
survivors at 18 months (130). However, according to a Cochrane review published in 
2013 of 11 randomized control trials with therapeutic hypothermia, moderate 
hypothermia also reduced mortality in term and late preterm newborns with HIE (153). 
There is evidence, which indicates, that treatment with moderate hypothermia after 
perinatal asphyxia led to improved neurocognitive outcome at school-age, however, 
the opposite has also been reported (130, 154). In the current clinical practice, 
therapeutic moderate hypothermia is induced within the first 6 h of life and is 
maintained for 72 hours (146). There is also evidence, that hypothermia initiated 
before 3 hours of life yields further benefits regarding outcome (155). The 
neuroprotective effects of hypothermia include the suppression of cerebral 
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metabolism, the reduction of excitatory neurotransmitter and free radical release, the 
inhibition of apoptosis, seizure prophylaxis and the amelioration of the 
neuroinflammatory response (146).  
In the past decades, novel neuroprotective strategies have been the primary 
focus of research in the field of perinatal HI brain injury (156). Many neuroprotective 
agents are being investigated, which either target the excito-oxidative cascade or the 
neuroinflammatory response. Blocking the inflammation after perinatal HI injury 
appears to confer neuroprotective effect, which could yield important therapeutic 
benefits (157-160). So far, few pharmacological agents proved to be effective in human 
preclinical trials (161). One of the most promising agents is erythropoietin (EPO), 
which has pleiotropic effects, such as neuroregenerative, angiogenic, anti-
inflammatory, and antiapoptotic effects (162-165, 161). Neurons, astrocytes and 
microglial cells all express EPO receptors, upregulate its expression upon HI insult 
and neuroinflammation (165) and EPO has been shown to exert anti-inflammatory and 
neuroprotective effects (166). A pilot trial of recombinant human EPO (rhEPO) in 
perinatal asphyxia showed that treatment resulted in improved EEG background 
activity and decreased serum NO levels at 2 weeks of age and fewer neurologic and 
developmental abnormalities at 6 months of age (167). However, in NAIS rhEPO 
treatment did not alter the extent of the brain infarction or neurodevelopmental 
outcome (168). Phase II and III clinical trials are currently in process (165). The 
administration of melatonin is also currently being assessed in clinical trials 
(NCT02621944). Melatonin also has pleiotropic effects, targeting several steps of the 
neuroinflammatory cascade and has been shown to exert antioxidative, free radical 
scavenging and anti-inflammatory effects (169, 170, 161). In piglets, administration 
of melatonin together with hypothermia decreased neuronal loss and preserved 
function (171). Xenon is another promising neuroprotective agent, showing synergic 
neuroprotective effects when combined with hypothermia (172). It is an antagonist of 
the NMDA glutamate receptor (173) exerting its protective effect primarily via 
inhibiting intrinsic apoptotic pathways. It has a very low blood-gas partition coefficient 
(174) enabling it to pass the through the BBB quickly. Xenon has been shown to reduce 
neuronal injury (175). There are ongoing clinical trials investigating the efficacy of 
hypothermia combined with xenon inhalation (NCT01545271). Doxycycline is an 
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important inhibitor of neuroinflammatory response, which reduces of IL-1β and TNF-
α expression and is approved for use in neonates, has few side effects, thus making it 
a promising candidate (176). Histone deacetylases exert pleiotropic anti-inflammatory 
and neuroprotective effects, via inhibiting the components excito-oxidative cascade, 
inhibition neuroinflammation and proapoptotic factors (177-179, 161). Further 
promising anti-inflammatory and neuroprotective agents include selective 
cyclooxygenase-2 inhibitors, resveratrol, N‑acetylcysteine, TNF-α soluble receptor, 
IL‑1ra and magnesium, which acts as an (endogenous cationic NMDA channel 
blocker) (180, 161).  
One intriguing recent discovery is, that mesenchymal stem cell (MSC) and 
neural progenitor cell therapy can protect the developing brain from HI injury. The 
hypothesis is, that MSCs are either able to “migrate to the site of injury, differentiate 
into specific cell lineages and exert anti-inflammatory effects” or stimulate the 
differentiation of endogenous precursors, inducing neuroregeneration and plasticity 
(77, 2). The strenuous efforts to find novel, individualized anti-inflammatory and 
neuroprotective strategies clearly outline the paramount importance of this aspect of 
managing neonates with perinatal HI brain injury. Overall, the past decade has brought 
much insight into the underlying pathomechanism of perinatal HI injury and potential 
ways to counteract the detrimental consequences, however, continuous efforts in this 





In developed countries, perinatal asphyxia continues to be a great burden on 
society as a leading cause of neonatal mortality and neurodevelopmental disability. 
Mortality and morbidity rates vary among the literature, but according to a recent 
review on outcome by Antonucci et al., in term neonates, the mortality rate is around 
20% and about 25% of survivors will develop neurological disabilities after perinatal 
asphyxia (146, 181, 182). Another review assessed the prevalence of individual 
neurodevelopmental disabilities after perinatal asphyxia and found, that of all children 
with adverse outcomes, 45% sustained “cognition and developmental delay or learning 
difficulties, 29% cerebral palsy, 26% blindness or vision defects, 17% gross motor and 
coordination problems, 12% epilepsy, 9% hearing loss or deafness, and 1% behavioral 
problems” (146, 183). A follow-up study by Van Handel et al. however, revealed, that 
when assessing at school-age, behavioral, social and attention problems were much 
more common in children, who sustained perinatal asphyxia (184). If neurological 
outcome was assessed in correlation with the initial clinical stage of HIE, mild insult 
lead to no serious neurodevelopmental alterations, whereas cognitive impairments 
and/or sensory-motor impairments or death occurred in 32% of children who initially 
had moderate HIE and 100% of children with severe initial HIE (185). However, 
further studies revealed, that subtler cognitive deficits and behavioral problems were 
also present following mild HIE (186). It appears, that the outcome is the most variable 
and the most challenging to predict in neonates with moderate HIE (146, 187, 188). 
A recent meta-analysis aimed to assess the prognostic value of currently 
available clinical diagnostic methods in patients with perinatal asphyxia and HIE. Data 
was collected from 29 studies and they found that overall, clinical and neurological 
examination and cerebral ultrasound had poor predictive value. In the first week of 
life, aEEG (sensitivity 0.93, specificity 0.90), conventional EEG (sensitivity 0.92, 
specificity 0.83), and VEP (sensitivity 0.90, specificity 0.92) had the best prognostic 
value regarding neurological outcome. From the imaging techniques, if performed in 
the first week of life, diffusion weighted MRI had the highest specificity (0.89), 
whereas T1/T2-weighted MRI (performed within the first 2 weeks of life) had the 
highest sensitivity (0.98). Early MRS had a sensitivity of 0.75 and poor specificity 




Figure 6. Prognostic value of the diagnostic methods available in the clinical 
practice. The original data which this figure is based on was published by van 
Laerhoven et al. (189) Pooled specificity and sensitivity values with confidence 
intervals are shown for each diagnostic test. 1The sensitivity and specificity of 
neurological examination is based on data from a single study (190). EEG = 
Electroencephalogram, aEEG = Amplitude-integrated Electroencephalogram, VEP = 
Visual evoked potential, SEP = Somatosensory evoked potential, MRI DWI = 
Magnetic resonance imaging, Diffusion-weighted imaging, MRS = Magnetic 
resonance spectroscopy.  
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2.3 NEONATAL ARTERIAL ISCHEMIC STROKE (NAIS) 
2.3.1  DEFINITION AND INCIDENCE 
The perinatal period carries the highest risk for stroke in the entire childhood, 
with almost similar incidence to that in the elderly population. “Perinatal stroke” is a 
broad term defining a group of heterogeneous cerebrovascular events which occur 
between 28 weeks of gestation and 7 days of age. However, many studies discuss the 
perinatal and the neonatal period together, extending inclusion to the first 28 days of 
life and the variation in terminology can be somewhat confusing. Although this 
definition also includes in utero stroke, most perinatal stroke events are thought to 
occur within a few hours to a few days post-delivery (191). 
Neonatal stroke can be categorized based on the distinct characteristics of the 
lesion. The most common subtypes in term neonates are neonatal arterial ischemic 
stroke (NAIS), primary Heamorrhagic stroke and cerebral sinus venous thrombosis 
(CSVT). Heamorrhagic events associated with prematurity, especially intraventricular 
hemorrhages account for a significant proportion of neonatal cerebrovascular events, 
however, we only included term neonates in our studies, therefore these events will 
not be discussed in detail. NAIS by definition is an arterial ischemic stroke, with 
clinical symptoms occurring in the neonatal period (within the first 28 days of life) 
which are supported by radiological evidence of a focal arterial infarction. (192-194). 
Many cases of perinatal stroke are only diagnosed later in infancy, with no evidence 
of an acute neurological event during the neonatal period. “Presumed perinatal stroke” 
refers to cases, where the diagnosis is made after 28 days of age, when NAIS most 
likely remained undetected in the acute phase (191). 
The exact incidence of neonatal stroke is difficult to determine and estimates 
are based on studies of neonatal seizures and population-based studies of childhood 
stroke (195). The incidence of neonatal stroke is estimated to be around 1/4000 live 
births, with NAIS occurring in 1/8000 live births.  
NAIS generally occurs in term neonates and presents a major risk for life-long 
motor, cognitive and behavioral disabilities ranging from fine motor impairments to 
unilateral cerebral palsy, which develops in around 20-30% of affected neonates. Thus 
NAIS is a leading cause of cerebral palsy (196). 
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2.3.2 RISK FACTORS 
The predisposing factors of NAIS are still under strong investigation and there 
is little consensus among field experts. There are several challenges in identifying the 
truly relevant risk factors and their possible impact on the course of AIS in neonates. 
Firstly, the number of studies is relatively low and those which are available are mostly 
case reports or small case series, only very few included enough cases to be 
representative. Secondly, the enrolling criteria and the recorded data are not 
homogenous, many studies include AIS and borderzone infarction as well and some 
do not distinguish between neonatal stroke cases and stroke occurring in older children 
(192). Another important challenge is the overlap of the risk factors and presentation 
NAIS with perinatal asphyxia. Furthermore, in the case of certain risk factors, similarly 
to HIE, it is very difficult to determine their place in the causal pathway. Authors Lee 
et al. propose the following possibilities for the role of factors such as fetal heart rate 
abnormalities in the development of NAIS (197):  
1) Plays a primary causal role 
2) Is on the causal pathway between preceding factor and NAIS 
3) Adverse effect of causal factor with no impact on NAIS 
4) Direct consequence of NAIS 
5) Combination of the above 
Further such factors include prolonged second stage of labor, vacuum 
assistance, and emergency cesarean section. These factors show a clear association 
with NAIS cases, however the impact of these factors is yet to established, and this 
must be considered when interpreting findings. Overall, there is little consistency 
among the different studies (193). Therefore, instead of true risk factors, it is more 





Table 3. Factors associated with elevated risk of neonatal arterial ischemic stroke 
(NAIS). The data were collected from the latest report of the largest database, the 
Canadian Pediatric Ischemic Stroke Registry (CPISR) and an American case-control 
study published in the Journal of the American Medical Association (JAMA). 1 
significant association in the CPISR (percentage of neonates affected), 
2 significantly difference compared to controls in the JAMA case-control study (198, 
197). 
Maternal factors Fetal factors 
Antepartum 
Primiparity1,2 (38.33%) Oligohydramnios2 
Diabetes/ Gestational Diabetes1 
(3.89%) 
Decreased fetal movement2 
Congenital heart disease1 
(12.28%) Hypertension1 (7.22%) 
Preeclampsia1,2  Prothrombotic disorders1 
(12.72%) Infertility1,2 (1.11%) 
Bleeding1 (3.89%) 
 
Streptococcus positivity1 (6.11%) 
Smoking1 (13.89%) 
Alcohol1 (7.22%) 
Recreational Drug Use1 (3.33%) 
Acute Viral Illness1 (3.33%) 
Antibiotic Use1 (3.33%) 
Chorioamnionitis1,2  
Intra-/ postpartum 
Pyrexia1 (16.67%) Fetal heart rate abnormality2 
Premature Rupture of Membrane1 
(10.56%) 
Cord abnormality2 
Bacterial sepsis1 (8.33%) 
Placental abruption1 (1.67%) Meningitis1 (3.95%) 







According to the latest data from the Canadian Pediatric Ischemic Stroke 
Registry (CPISR), which is the largest database available to date, an identifiable risk 
factor was only present in 56% of neonates with stroke, while the rest of the NAIS 
cases were considered to be of idiopathic origin. Furthermore, 21% of neonates with 
AIS also presented with asphyxia at birth (198). The identifiable risk factors of NAIS 
however appear to be specific for the perinatal period and can be distinguished from 
the risk factors of stroke in older children or adults (192). Most NAIS cases are 
believed to be of multi-factorial origin, in an American case-control study, the presence 
of three or more risk factors increased the risk of perinatal stroke 25-fold (197), 
therefore identifying predisposing factors has been in the limelight of research.  
One independent risk factor, which was found relevant in almost all studies was 
perinatal inflammation (196). Several markers of perinatal inflammation appear 
consistently as risk factors for NAIS, most importantly maternal fever and neonatal 
infection. In the CPISR bacterial sepsis, shock or meningitis was found in altogether 
15% of NAIS cases, and there is consequent documentation of arterial ischemic stroke 
due to focal arteritis as a classical complication of bacterial meningitis (198-202). In 
the CPISR, maternal fever was documented in 17% and premature rupture of 
membranes in 11% of NAIS cases (198). Chorioamnionitis in the absence of fetal 
distress was significantly associated with NAIS (197). Maternal fever is a classic 
indicator of chorioamnionitis, however, most studies did not include histological 
examination of the placentae, since NAIS is typically diagnosed within days after 
delivery. Studies, which are available indicate a strong association between NAIS and 
histological chorioamnionitis (203, 197). The need for large-scale placental tissue 
banking to understand the contribution of antenatal exposure to inflammation to the 
pathogenesis of NAIS has been raised by experts (193). 
Further associated maternal risk factors include primiparity (38%), gestational 
diabetes, hypertension, preeclampsia (13%) (198), thrombophilia, including 
antiphospholipid syndrome, history of infertility, smoking and drug use. 24% neonates 
were delivered by Caesarean section. Many neonates with AIS needed supportive care 
following birth, 39% of neonates needed supplemental oxygen, 12% required bag and 
mask ventilation, 18% had to be intubated and in 7% of all cases a complete 
cardiopulmonary resuscitation was necessary (198).  
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Among fetal risk factors, one of the most prominent is congenital heart disease 
which was present in 12% of NAIS patients according to the CPISR. There has been 
much interest in the role of genetic prothrombotic disorders in the etiology of NAIS, 
and several studies show a positive correlation between NAIS and different 
prothrombotic states (204). A meta-analysis of observational studies on prothrombotic 
disorders found thrombophilia to be a risk factor for both AIS and sinovenous 
thrombosis in all age groups during childhood (205). However, studies based on 
clinical thrombophilia testing found less correlation and raised awareness to the 
challenges and variety of laboratory methods (206). Other studies debate the relevance 
of prothrombotic disorders, arguing that most studies which linked genetic 
thrombophilia to NAIS were based on a heterogeneous cohort of term, late preterm, 
and early preterm neonates, thus making data less reliable (196, 201).  The impact of 
thrombophilia on the incidence and recurrence of NAIS remains a focus of 
investigation, however, it appears to be clear, that thrombophilia alone can rarely 
account for all the cases of perinatal stroke (193). 
2.3.3 PLACENTAL PATHOLOGY 
Among other risk factors, pathological placental alterations have been 
implemented to contribute to the development of perinatal stroke. In one case-series 
authors aimed to systematically characterize placental pathology along the assessment 
of maternal and fetal risk factors in 5 NAIS and 7 CSVT cases (203).   
In their cohort, 10 out of 12 neonatal stroke patients (83%) had pathological 
placental alterations, and in several cases, there was evidence of multiple types of 
lesions. Most patients also had several prenatal or neonatal risk factors, supporting the 
theory, that neonatal stroke might be the end result of a combination of predisposing 
and triggering factors. 50% of neonates with stroke had lesions consistent with 
thromboinflammatory processes, such as fetal thrombotic vasculopathy, acute 
chorioamnionitis, chorionic vessel thrombosis, stem vessel thrombosis or umbilical 
vein thrombosis, which could serve as the source of cerebrovascular 
thromboembolism, although the impact of such alterations is difficult to determine 
without control data. Fetal thrombotic vasculopathy is a disorder, when thrombosis 
develops in the fetal side of the placental circulation and it has been associated with 
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systemic neonatal thromboembolism, including cerebral embolism (207).  Histologic 
evidence of a sudden catastrophic event, such as retroplacental hematoma, umbilical 
vessel occlusion or umbilical cord entanglements was also present in nearly half of the 
cases. Authors hypothesized that the blood stasis could lead to clotting and umbilical 
vessel thrombosis, which could be a source of emboli. 
Placental lesions indicating decreased placental reserve were present in 3 cases. 
Placental insufficiency and infection are known to activate the inflammatory cascade 
and were shown to increase the production of pro-inflammatory cytokines such as IL-
6, IL-8, and TNF-α in response to vascular compromise and oxidative stress (208-210). 
Decidual cytokines have been shown to pass through the placental membranes and 
appear in the fetal circulation, and in clinical chorioamnionitis, elevated concentrations 
of cord-blood cytokines have been associated with neurological symptoms, such as 
seizures (211, 212). In vitro stimuli of hypoxia and growth restriction have been 
observed to induce TNF-α production leading to fibrin deposition in placental villi, 
which is able to alter the endothelium to create a thrombogenic surface and thus 
activate the coagulation cascade (213, 203). The role of the activated inflammatory 
and coagulatory cascade in the development of ischemic neonatal brain injury is 
supported by much of recent years’ research and remains a central topic of interest. 
Authors concluded, that the placenta could serve as an important source of embolism 
and cytokines and pathological alterations could contribute to the development of 
perinatal stroke (203).  
2.3.4 PATHOPHYSIOLOGY  
Different neonatal cerebrovascular events may have distinct etiological 
backgrounds. NAIS by definition is an arterial infarction, which is assumed to be the 
result of a thromboembolic event leading to a focal ischemic lesion in the area of the 
affected cerebral artery. The thrombi are presumed to originate from intra- or 
extracranial vessels, the heart or the placenta (192). The pathophysiology of NAIS is 
poorly understood and disease specific preventive measures, prognostic factors and 
therapeutic strategies are not available (193). 
Interestingly, NAIS almost always occurs in intra-cranial arteries developing 
from the carotid arterial tree, i.e. the proximal parts of the anterior cerebral artery 
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(ACA), the middle cerebral artery (MCA) and the posterior cerebral artery (PCA)—
while the basilar artery and the extra-cranial arteries are left unaffected (214-216). 
Similar to adults, the area of the MCA is the most common localization of the ischemic 
lesion in neonates as well, with 83% of focal events affecting this area, of which 66% 
are left sided, resulting in a higher incidence of right sided congenital hemiplegia (217, 
194).  
According to the classic pathophysiological hypothesis the origin of the 
thrombi are proximal sources such as the placenta and the umbilical vessels (191, 214). 
The thrombi are supposed to undergo right to left shunting via the patent foramen ovale 
and lead to cerebral embolism and ischemic lesions, which are often multifocal in 
NAIS. The pathological findings in NAIS are easy to differentiate from disorders 
connected to decreased cerebral perfusion, such as border zone ischemia, which is 
usually bilateral and localized to the area between two major vessel territories (192). 
It appears, that placental abnormalities might play an important role in the 
development of thromboembolism in the neonate. The recurrence rate of NAIS is 
almost zero, supporting theories that emphasize the role of factors only present 
perinatally (193). There are data from small clinical studies, that indicate a direct 
correlation between pathological placental alterations, especially placental 
inflammation or chorioamnionitis and NAIS (203, 197). Maternal and fetal/neonatal 
inflammatory biomarkers are currently under strong investigation with the hope, that 
identifying key inflammatory signatures may help in gaining a better understanding of 
the disease pathology and might open the way for better prognostic and diagnostic 
strategies (193).  
Although there is evidence supporting the role of placental inflammation in the 
development of NAIS (193), they can only be identified in some of the cases and this 
hypothesis does not give a plausible explanation to why NAIS is almost exclusively 
affecting the intracranial arterial territories developing from the carotid arterial tree, 
while the incidence of basilary arterial or extracerebral infarcts is negligible (191). In 
recent years, angiographic alterations were described, raising the notion that local 
arterial wall defects and in situ thrombus generation might also play an important role 
in the development of NAIS (218, 206). Guiraut et al. hypothesized that maternofetal 
inflammation could induce focal arteritis specifically in the intracranial arteries 
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developing from the carotid arterial tree, which are susceptible to NAIS (196). Using 
a preclinical rat model of chorioamnionitis, they were able to demonstrate, that classic 
prothrombotic stress on the MCA, when applied alone was not enough to induce NAIS, 
however, when combined with in-utero exposure to inflammation inducing agent 
lipopolysaccharide (LPS), was able to lead to the classical symptoms of NAIS and 
motor impairment. They also examined the walls of arteries susceptible to NAIS and 
found that the constitutive expression of certain pro-inflammatory cytokines, i.e. TNF-
α and IL-1β was higher in the susceptible intra-cerebral arteries than in extra-cerebral 
arteries. Furthermore, pups born from LPS-exposed dams developed a specific 
cerebral arteritis with increased presence of inflammatory cells (macrophages) and 
elevated levels of pro-inflammatory cytokines IL-1β, TNF-α, MCP-1 and increased 
IL-1/IL-1 receptor antagonist (ra) ratio in NAIS susceptible arteries, but not elsewhere 
(214).  
There is further evidence supporting the role of prenatal inflammation in 
sensitizing the brain for postnatal HI injury (219-221). The initial hypoxic insult leads 
to primary energy failure, oxidative stress and excitotoxicity resulting in widespread 
necrosis and necroptosis within the first 6 hours of the insult (222-224). Neural tissue 
damage could be aggravated by previous sensitization due to inflammation, which 
could lead to increased oxidative stress and an increased production of pro-
inflammatory cytokines (225, 220, 226-229).  
Based on these findings a novel pathophysiological hypothesis is being raised, 
which considers the complex and bidirectional relationship of coagulatory and 
inflammatory pathways (230). According to it, the development of NAIS can be 
described as the result of “multiple hits”, originating from both perinatal inflammation 
and hypoxia–ischemia (HI) (196). Guiraut et al. have identified three major risk 
factors, the combination of which could lead to NAIS: (i) materno-fetal inflammation 
leading to focal arteritis in arteries susceptible to NAIS, (ii) a window of susceptibility 
in the development of the neonatal brain and (iii) the physiological pro-coagulatory 
state of the perinatal period aggravated by the inflammatory response (214).  
The role of the inflammatory pathway in the development of an ischemic brain 
injury is supported by much of recent years’ research data. Not only does it appear to 
be a critical step in the pathomechanism of neonatal stroke, but the subsequent 
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neuroinflammatory response to the ischemic brain injury is also a common feature of 
perinatal asphyxia and NAIS. The most important aspects of the neuroinflammation 
are the production of inflammatory cytokines, the migration of leukocytes into the 
brain tissue leading to necrosis and apoptosis. T lymphocytes appear to play a central 
role in the development of an ischemic brain infarct, CD4+ (Cluster of Differentiation) 
and CD8+ T cells migrate to the CNS already a few hours after a HI injury. The 
prevalence of T lymphocytes reaches its maximum around 3-4 days after the HI injury 
and the inhibition of T cell trafficking to the CNS ameliorates the detrimental effects 
of neuroinflammation after AIS (231, 232). T cell deficiency has also been shown to 
reduce infarct size and improve neurological outcome in murine ischemic stroke 
models (233-235).  
Human experimental data on the role of inflammatory markers in shaping the 
course of NAIS is scarce, one small case-control study aimed to describe the levels of 
different cytokines in the plasma of pediatric AIS patients. Elevated levels of TNF-α, 
IL-2, IL-6, and IL-8 were observed 6 months following AIS compared to healthy 
controls. No alterations were present in soluble endothelial protein C receptor, IL-11, 
and FVIII median levels (236). The limitation of this study is that they included both 
neonatal and pediatric stroke cases (from birth until 18 years of age), which are now 
recognized as distinct clinical syndromes. However, these results indicate that an 
ongoing inflammation could be observed up to 6 months following AIS, although, no 
information is available regarding the acute phase of NAIS. Many studies have been 
focusing on the immunological consequences of AIS in adults and several cytokines 
have been suggested to play an important role in the development of the ischemic 
lesion. Pro-inflammatory cytokines IL-1β, IL-8, MCP-1, TNF-α and IFN-γ appear to 
exacerbate cerebral injury, whereas anti-inflammatory cytokines such as TGF-β and 
IL-10 appear to be neuroprotective (237-239). Although the immune system of 
neonates differs from that of adults on many accounts, the inflammatory network 
appears to play a similarly critical role in the course of an ischemic brain injury. 
Identifying the key players of the inflammatory and apoptotic pathways is a 
cornerstone of current research focusing on NAIS and neuroinflammation, since the 
time period after a hypoxic injury could be important for targeted intervention (233, 
240, 196, 241).  
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2.3.5 CLINICAL PRESENTATION AND DIAGNOSIS 
The greatest challenge in the diagnosis of perinatal stroke is that unlike in older 
children and adults, the clinical presentation in neonates is often subtle and non-
specific (192). Neonates rarely present with focal signs such as unilateral motor deficit. 
The most common clinical manifestation is focal or generalized seizures in the first 
12-72 hours of life, which are estimated to occur in 70-90% of neonates. According to 
the Canadian Stroke Registry, neonates with stroke presented with seizures in 88% of 
the cases, whereas focal neurological deficits, mainly hemiparesis was present in only 
12% of the cases (198). Studies focusing specifically on neonatal seizures have raised 
attention to the incidence of perinatal stroke, which was found in 12-14% of neonates 
with seizures, making stroke the second most common cause of seizures in term 
neonates (242, 243). Many neonates also develop generalized encephalopathy, with 
irritability, hypertonia or lethargy and hypotonia and poor feeding present in 36-63% 
of cases (191). The neurological examination of NAIS patients usually results in non-
specific findings such as general hypotonia and lethargy.  
The incidence of NAIS is still hard to determine and many cases remain 
undiagnosed, since affected neonates may present with very subtle or no symptoms 
during the neonatal period. Thus NAIS is diagnosed retrospectively in infancy, when 
the most common signs are early hand preference and delayed motor milestones, 
however hemiparesis, focal seizures or infantile spasms may also occur. At this time, 
neuroimaging may reveal signs of chronic focal injury (191, 192). 
Another challenge in the timely diagnosis of NAIS is that the risk factors and 
clinical signs of global hypoxic-ischemic encephalopathy due to perinatal asphyxia 
show a significant overlap with NAIS and the two often co-occur (206, 193, 244). 
Differentiating between the two syndromes is a challenging, some studies list perinatal 
asphyxia as an independent risk factor for NAIS (192), and many neonates develop 
general encephalopathy after NAIS, while the neuroinflammation following the initial 
hypoxic insult appears to be a common feature of the two. 
Although trends are improving, recent results from the CPISR still indicate 
delayed diagnosis due to the lack of specific clinical features and the high rate of false-
negative results with cranial ultrasound and CT scans as a major challenge in NAIS. 
Authors emphasize the importance of high awareness to a possible AIS in neonates 
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and the need for timely MRI scanning (198). The best modality for detecting and 
characterizing NAIS and differentiating it from diffuse hypoxic-ischemic 
encephalopathy is MRI with vessel imaging (Figure 7). It is the most sensitive at 2-4 
days after the hypoxic injury, however, restricted diffusion on diffusion-weighted 
imaging can indicate a stroke earlier (191).  
 
Figure 7. MRI and MRA images of the brain of a term neonate with NAIS.  
Images show a large infarct in the area of the MCA. This image was published by 
Bernson-Leung et al. (191) with the following legend: Term neonate presented with 
right eye twitching at delivery. Axial images showed restricted diffusion indicating 
acute ischemia (bright on trace image [A] and dark on ADC map [B]) occupying the 
entire left MCA territory (arrows). C. Sulcal effacement and obliteration of the gray-
matter/white-matter junction are seen on the axial T2 sequence. D. Magnetic 
resonance angiography showed absent flow signal in the expected location of the MCA 
due to occlusion (solid arrows indicate expected course as compared to white outlined 
arrows that indicate course of right MCA). He developed infantile spasms at 5 months. 
At 13 months, he had a spastic hemiparesis, could sit but not crawl, and had no specific 




The diagnosis of NAIS is often delayed, due to the prenatal onset or absence 
of specific signs, therefore the primary therapeutic aims are prevention and post-insult 
anti-inflammatory treatments (196). Currently no disease-specific therapeutic methods 
are available in the acute care of NAIS patients. Therapy mainly consists of intensive 
care, circulatory support and seizure prophylaxis. Recurrence rates are very low (1-
2%) and occur mainly in cases with identified cardiac abnormalities or coagulation 
disorders, therefore chronic anticoagulatory or anti-platelet therapy is not 
recommended (191). The long-term care of these patients is primarily centered around 
early rehabilitation, with the hope, that the neuroplasticity of the developing brain can 
be harnessed to minimize neurological deficits. More and more studies are available 
on the recovery of function after NAIS, providing valuable insight in the mechanisms 
of recovery in the immature brain (193). 
A central question regarding anti-inflammatory therapeutic methods following 
NAIS is the potential value of therapeutic hypothermia, which is currently the standard 
of care for term neonates with perinatal asphyxia resulting in HIE. There is substantial 
evidence supporting the role of hypothermia in reducing mortality and improving 
neurological outcome in neonates with hypoxic ischemic encephalopathy (130). 
Hypothermia has been shown to reduce infarct size in animal models of focal cerebral 
ischemia (245), decrease cytokine levels in HIE (246) and there is evidence that 
hypothermia might lower the risk of seizures after perinatal stroke and thus improve 
outcome (247). There is currently an ongoing discussion within the scientific 
community about extending the indication of therapeutic hypothermia to include new 
categories, such as preterm neonates with HIE and perinatal stroke, however there are 
still many concerns which need to be clarified before new therapeutic methods can be 
introduced into the clinical practice (233, 245).  
2.3.7 PROGNOSIS AND OUTCOME 
Disease specific prognostic markers are currently not available for neonatal 
stroke. Data analysis from the largest database, the CPISR revealed, that certain 
aspects of the clinical presentation and the course of NAIS can be associated with poor 
outcome. Predictors of poor outcome were decreased level of consciousness, 
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nonspecific presentation and basal ganglia stroke location. Posthoc analysis of 
correlation between clinical presentation and outcome showed that neonates 
presenting with cardiorespiratory symptoms such as apnea or cyanosis had the highest 
chance for poor outcome (198). Abnormal EEG during the first post-stroke week and 
internal capsule involvement were associated with the development of hemiplegia 
(248). Infants diagnosed following the neonatal period also had a higher chance for 
adverse neurological outcome (192, 249).  
Neonatal stroke is still a major cause of disability in the developed countries. 
Data from the CPISR indicates, that only 40% of neonates who suffered stroke show 
a normal long-term normal neurological outcome. The mortality rates in the acute post-
stroke phase have reduced to 9%, however, long-term disability is still a great issue. 
Early outcome data showed, that 70% of neonates showed no deficits at the time of 
discharge, 20% showed mild, 6% moderate and only 2% severe neurological deficit. 
On the contrary, long-term follow up revealed, that neurological deficits increased 
from 30% to 60% among neonates, with 39% of neonates showing a worsening 
neurological function over time, while only 6% showed improvement. Late seizures 
occurred in 17% of neonates. This clearly shows one of the important challenges in 
the long-term care of neonatal stroke patients, which is the emergence of novel 
neurological deficits with time. These deficits could indicate the role of chronic 
neuroinflammation in long term functional recovery, however could also be a result of 
the initial insult, with the symptoms manifesting only when the child’s 
neurodevelopment reaches a certain point (for example in the case of speech deficits) 
(250). Long term outcome data showed mild deficit in 33% of cases, moderate in 19% 
and severe deficit in 8% of cases. Interestingly, basal ganglia stroke in neonates was 
associated with a four-fold increase in the chance of poor outcome, which could be 
due to the disruption of the developing neural networks necessary for cortical 
migration in the periventricular zone of the immature brain of neonates who suffer 
subcortical infarcts (251). Authors argue, that the high rate of adverse neurological 
outcome supports the vulnerability hypothesis and not the enhanced plasticity 






2.4.1 HYPOXIA-INDUCED NEUROINFLAMMATION 
Inflammation of the CNS or neuroinflammation is now recognized to be a 
common consequence of hypoxic brain injuries, including perinatal asphyxia and 
stroke. The brain injury following perinatal hypoxia-ischemia evolves over time as a 
result of several mechanisms, however neuroinflammation is considered to be a major 
pathogenic factor (180). The inflammatory response is not limited to the CNS, but can 
also be detected systemically (255, 256). The level of immune activation and the 
complex neuro-immune cross talk appear to determine the severity of the brain 
damage, influencing long-term outcome. 
The neuroinflammatory response can be divided to three phases, an early 
primary, a delayed secondary and a chronic tertiary phase. The initial insult leads to 
insufficient glucose delivery to the highly sensitive developing brain tissue, which 
triggers a metabolic chain reaction resulting in the exhaustion of the energy stores of 
the neuronal tissue (primary energy failure). This, along with the direct consequences 
of cellular hypoxia leads to extensive cellular damage (50, 257, 161). Inflammatory 
signals are released within minutes, leading to microglial activation followed by 
systemic immune activation. Microglia and astrocytes release pro-inflammatory 
cytokines and chemokines leading to the disruption of the BBB, allowing peripheral 
leukocytes to migrate to the CNS. In comparison with adults, in whom leukocyte 
infiltration and cytokine production follows microglial activation within hours, 
neonatal immune responses are triggered almost immediately after cerebral ischemia 
and continue for weeks (258, 259, 255).  
The second phase is initiated after approximately six hours and is mainly 
characterized by the excessive production of pro-inflammatory cytokines, 
chemokines, NOS, ROS, RNS, excitatory amino acid agonists, and death receptor 
agonists by both the activated (intrinsic) microglia and the infiltrating monocytes and 
T cells (260-262). This leads to excitotoxicity, apoptosis and further necrosis resulting 
in “delayed neuronal death” (112, 69), which is responsible for a large percentage of 
the total neural cell loss regardless of the severity of the initial hypoxic-ischemic insult. 
Further contributing factors to the brain tissue loss include axon and myelin injury, the 
DOI:10.14753/SE.2020.2341
49 
loss of oligodendrocyte progenitors and mature oligodendrocytes (263).  
The tertiary phase of brain damage is defined by authors Fleiss and Gressens 
as a collective result of those processes, which “worsen outcome, predispose a patient 
to further injury, or prevent repair or regeneration after an initial insult to the brain” 
(Figure 8) (118). They propose, that the tertiary phase might persist for months or years 
after the initial injury, contributing to the long-term consequences of 
neuroinflammation. Their aim is to raise awareness to the notion, that there might be 
active processes long after the initial brain injury, and that this tertiary, latent phase of 
neuroinflammation would be a crucial time for targeted intervention. Therapeutic aims 
include the regulation of the sustained microglial activation and inflammatory 
processes and the modification of adverse epigenetic alterations. Although the data 
from animal models and studies on adults are intriguing, little is known about the 
impact of these tertiary processes on neurodevelopmental outcome in neonates. 
Learning more about the events of this chronic phase of neuroinflammation in human 
perinatal HI brain injury could open new possibilities for individualized therapy and 
targeted intervention to improve long-term neurological outcome (118).  
According to the hypothesis of Fleiss and Gressens the key features of this 
phase are:  
1) Persistent inflammation 
2) Aberrant gliosis 
3) Epigenetic changes 
4) Consequent blockade of oligodendrocyte maturation 






Figure 8. Schematic image of the key features of the tertiary phase of 
neuroinflammation. This image was published by Fleiss and Gressens (118) with the 
following legend: Changes in oligodendrocytes, maturational blockade, and the 
production of glial scar products leading to decreased myelination, changes to glia, 
astrogliosis and microgliosis, and possible changes in EAA bioavailability are shown. 
Also shown is the NVU, a possible target for novel therapeutics because of its ability 
to mediate transmigration of inflammatory mediators. EAA= excitatory aminoacid. 
NVU= neurovascular unit. 
1) Persistent inflammation 
A growing body of evidence indicates the presence of persisting 
neuroinflammation long after the initial brain injury. In non-human primates 
microglial activity and cytokine production was increased 12 months after traumatic 
brain injury (266). Human in vivo data from PET (positron emission tomography) 
scans indicate persisting microglial activity 10 years after traumatic brain injury, which 
correlates with worse neurological outcome (267). T lymphocytes and other 
inflammatory cells and signals can be detected for months following the initial HI 
brain insult (268) Microglial cells also play a key role in the maturation and 
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development of the CNS and authors Fleiss and Gressens propose, that sustained 
microglial hyperactivity could also have an impact on synaptic pruning, neurogenesis, 
pathway excitability and memory, which could predispose the brain to cognitive 
impairments (118). 
2) Reactive gliosis 
Reactive astrogliosis is a key protective mechanism during the acute phase of 
HI brain injury, which limits the leaking of the BBB by creating a barrier around the 
site of injury (118). Astrogliosis is a key feature of the long-term consequences of HIE. 
Activated astrocytes and components of glial scars have been shown to inhibit axonal 
regrowth and remyelination, inhibiting regeneration and repair processes even months 
after the initial phase (118, 269-271) Astrocytes also play a key role in regulating the 
level of neurotransmitters, and decreased glutamate transporter expression has been 
shown to persist until at least 21 days after perinatal HI brain injury in rats (272), which 
could play a role in sustaining long-term excito-oxidative processes.  
3) Epigenetic changes and consequent inhibition of oligodendrocyte 
maturation 
Epigenetic modifications are by definition “the enzymatic changes of 
transcription via the modification of permissive tags on histones or DNA and 
microRNA-mediated alterations of translation” (118). Epigenetic alterations therefore 
play a pivotal role in the normal development of the brain and they have been shown 
to be a key factor in transmitting the long-term consequences of brain injury, “such as 
cognitive, motor and behavioral impairments” (118, 273). Evidence indicates, that 
these epigenetic changes are associated with for example cognitive decline, after 
traumatic brain injury (274, 275). Authors emphasis of the role of epigenetic changes 
in delayed oligodendrocyte maturation and consequent white matter injuries (118). 
Recently Favrais and Fleiss et al. have also been able to demonstrate, that chronic 
perinatal inflammation induced by exposure to IL-β in the first days of life lead to 
oligodendrocyte maturation failure persisting until adulthood and resulting in 




4) Sensitization to further injury 
According to Fleiss and Gressens the events of the tertiary phase of 
neuroinflammation could induce a so-called persistent glial priming, leading to 
malfunctional pro-inflammatory signaling and alterations in the production of 
excitatory neurotransmitters, which could sensitize the brain to following injuries (118, 
276, 277). In support of this hypothesis, perinatal exposure to LPS and other viral and 
bacterial mimetics have been shown to reprogram neuroimmune responses and 
increase the vulnerability of the brain for HI injury and inflammation in the adulthood. 
This was associated with accelerated cognitive decline and aging (278-280, 221). 
Overall, hypoxic-ischemic injury effects the developing brain very differently 
than the adult brain mainly because of the immaturity of the CNS and the immune 
system. The main characteristics of the neuroinflammatory response following 
perinatal HI injury are summarized on Figure 9. The age-specific inflammatory, 
oxidative and excitotoxic mechanisms make the embryonic and early postnatal brain 
especially susceptible to hypoxic-ischemic injury and increase the chance of long-term 
neurological consequences and mental health disorders (50, 257, 161). 
The detrimental consequences of neuroinflammation have been extensively 
studied, however, the aspects of the inflammatory response that are beneficial for the 
CNS regeneration have only recently been brought to light (281, 282). While excessive 
neuroinflammation contributes to the loss of oligodendrocytes and demyelination, it 
has become evident that a certain level of neuroinflammation is necessary for CNS 
recovery. Beneficial effects of neuroinflammation include neuroprotection, the 
mobilization of neural precursors for repair and axonal regeneration (283). The 
challenge is to understand and harness the beneficial aspects of neuroinflammation to 





Figure 9. Summary of the progress and development of perinatal hypoxic-ischemic 
brain injury and the following neuroinflammatory response. This figure was created 
from the information in the chapter above, based on the following references: (118, 
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2.4.2 CELLS PARTICIPATING IN THE NEUROINFLAMMATION 
2.4.2.1 MICROGLIA 
The first responding cells to the CNS hypoxia are the microglial cells, the 
residual immune cells of the brain which are derived from embryonic hematopoietic 
precursors that enter the CNS before birth and persist until adulthood (285, 286). In 
resting state, the microglial cells are responsible for immune-surveillance through their 
ramified processes, which continuously expand and retract to monitor the CNS 
microenvironment. Upon a hypoxic cerebral insult, they sense the inflammatory 
signals released from the injured neurons and glial cells and become activated within 
minutes (287, 288). Following activation, they gain macrophage-like functions such 
as phagocytosis, cytokine production, antigen presentation and matrix 
metalloproteinase (MMP) release (257). As a combined result of hypoxia and the 
inflammatory mediators, the tight junctions of the of the BBB start to break down (289) 
and large amounts of peripheral leukocytes begin to infiltrate the CNS, aggravating 
the inflammatory response, which leads to further neuronal injury and apoptosis (284). 
Depending on the local inflammatory milieu, microglial cells are able to switch 
between classical activation (M1), characterized by cytokine-, chemokine- and 
reactive intermediate production and alternative activation (M2), which leads to the 
clearance of reactive species and anti-inflammatory signaling (290, 291). M1 type of 
activation is associated with increased neuronal cell loss compared to M2 type 
activation and thus the phenotype of microglial activation likely plays an important 
role in setting the course of the neuroinflammatory response (292, 257). 
The aggregation of microglial cells in the dental gyrus and the hippocampus 
appears to be a characteristic result of perinatal asphyxia. In one study, where 
hippocampal samples from 178 children were assessed retrospectively authors found 
that neonates who died from HIE had a dense infiltrate of microglial cells in the 
polymorphous layer of the dentate gyrus, which was missing in infants who died of 
other acute causes such as sepsis or were older than 9 months (293). Data from animal 
models of hypoxia-ischemia also support the pivotal role of microglial activation in 
the neuroinflammatory process. Microglial cells have been shown to accumulate 
around the hippocampus, the periventricular and the subcortical white matter after 
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activation due to HI injury in preterm sheep (294). Amoeboid microglial cells on the 
other hand showed an almost immediate response to HI injury in a murine model, 
showing aggregation around the brain infarct. These microglial activation lead to the 
release of pro-inflammatory cytokines, free radical generation and excess glutamate 
release, which resulted in oligodendrocyte loss, demyelinisation and BBB breakdown 
(260, 295, 296, 257). Overall, microglial activation appears to be a key factor in the 
course of the neuroinflammatory response and is in the limelight of research.  
2.4.2.2 ASTROCYTES 
Astrocytes, along microglial cells are also activated within minutes of a 
hypoxic cerebral injury. Animal models of HI have revealed, that the astrocytes of a 
neonatal brain are rather resistant to hypoxia and readily proliferate around the necrotic 
area (257). Upon activation, astrocytes undergo characteristic changes in their 
morphological and functional, which results in reactive astrogliosis leading to the 
formation of glial scars in the affected cerebral region, which appears to be an 
important feature of perinatal ischemic brain injury (297-299, 161). During the 
development of the human CNS, astrocytes only become reactive to HI injury from 
the 20-23rd gestation week onwards (300). 
Astrocytes appear to have a dual role in the development of an ischemic brain 
injury. On the one hand, activated astrocytes are an important source of pro-
inflammatory cytokines such as IL-6, TNF-α, IL-1α and β and IFN-γ and neurotoxic 
substances such as NO, which can aggravate the neuronal damage by inducing 
apoptosis and inhibiting neurogenesis (301, 302). Reactive astrocytes also play a 
central role in regulating the migration of immune cells from the periphery to the site 
of injury via chemokine signals (303, 304). They also induce chemokine and cytokine 
production in neuroblasts and angioblasts (305). However, there is also much evidence 
of the neuroprotective role of activated astrocytes, which they exert by secreting anti-
inflammatory agents, glutathione and superoxide dismutase (306-308), facilitating 
extra-synaptic glutamate uptake and thus protecting from excitotoxicity (309-311) and 
maintaining ion gradients (257, 312, 313). This is further supported by studies which 
show that in the absence of functional astrocytes, the neuronal injury is aggravated 
(314, 315). One mechanism of protection might be the conversion of astrocytes into 
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neural progenitor cells promoting neural cell proliferation, survival, migration and 
differentiation, which has been shown in adults (316, 161). How the pro- and anti-
inflammatory effects of astrocytes are regulated and how this affects the course of a 
perinatal hypoxic brain injury is however yet to be understood. 
2.4.2.3 NEUTROPHILS 
The contribution of neutrophils to the neuroinflammation after HI in adults is 
well established (317, 318). In adults, neutrophils migrate to the site of injury within 
6 hours and exacerbate the inflammation by producing ROS and releasing 
inflammatory agents such as MMP-9 (257). However, neonates appear to have 
diminished ability to mount neutrophil response to hypoxia-ischemia (257, 161). The 
migration of neonatal neutrophils through the BBB appears to be impaired (319-321), 
however, they do appear in the cerebral vessels in the first few hours after HI (260). 
Furthermore, neutropenia induced before HI was beneficial, while removing 
circulating neutrophils after the hypoxic event or inhibiting neutrophil function did not 
bring about any benefits (321, 322). Overall it appears, that neutrophils have a lesser 
role in the neuroinflammatory process in neonates than in adults (257, 161). 
2.4.2.4 LYMPHOCYTES 
The role of the adaptive immune system in the development of perinatal 
hypoxic brain injury is much less studied than that of the innate immune system. The 
detrimental effect of T lymphocyte activation following acute ischemic brain injury in 
adults has been shown by several studies. Yilmaz et al. were able to show, that Rag 
(Recombination activating gene) 1−/− mice lacking both T and B lymphocytes had 
largely reduced infarct size and better neurological outcome than wild type (WT) mice 
after cerebral ischemia. However, when splenocytes from WT mice were transferred 
to Rag1−/− mice, the neural damage became comparable in the two groups, indicating 
that the lymphocytes determining the extent of cerebral damage after HI injury migrate 
from the periphery to the brain (257, 235). T and B lymphocytes have been shown to 
appear in the ischemic brain lesion within hours (323, 324) and can be detected for 
months after HI in adults (268). After perinatal hypoxic-ischemic brain injury, the 
influx of lymphocytes into the brain is less profound, probably due to the immaturity 
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of the immune system (260, 325). Therefore, lymphocytes were thought to be of 
minimal impact on the course of perinatal neuroinflammation, however, recent years’ 
research results brought their role in regulating and maintaining the 
neuroinflammatory response into light. 
Winerdal et al. aimed to characterize the recruitment and activation of T-
lymphocytes to the site of the injury following a hypoxic-ischemic insult in a mouse 
model of perinatal hypoxic brain injury. The link between the innate and adaptive 
immune system are the antigen presenting cells (APCs) of the brain, which were the 
activated microglial cells 24 hours after HI. One week later however, a second peak of 
APC activation was observed, and the majority of these cells were bone-marrow 
derived APCs, which probably play a central role in sustaining the inflammatory 
cascade. Increased MHC-II expression and the expression of T cell co-stimulatory 
CD86 markers was found in APCs already 24 hours after the insult and this could still 
be observed 3 months later. Similar signs of activation were found in the periphery as 
well, indicating the presence of massive systemic effects alongside the localized 
immune response (255). These results indicate, that the large-scale priming of the 
adaptive immune system is present after perinatal hypoxic brain injury (268). 
In line with these findings, the infarcted brain area contained a substantial 
amount of CD3+ T lymphocytes two weeks after the HI injury, which were not present 
in the unaffected areas at all. By assessing the temporal alterations of T lymphocytes 
via flow cytometry, Winerdal et al. were able to demonstrate, that there is a substantial 
influx of CD4+ T-helper lymphocytes in the acute phase, which peaks one week after 
HI, and that the recruitment of cytotoxic CD8+ lymphocytes follows a week later and 
peaks after 2 weeks. The T cells which initially entered the CNS expressed naïve T-
cell marker CD45rb, which was downregulated by 3 months. At the same time, T cells 
began to express activation markers such as CD69 and CD25, which were upregulated 
even 3 months after the injury, indicating the local activation and maturation of T cells 
by time. In addition, normally non-immunogenic brain homogenate was able to elicit 
proliferation in peripheral splenocytes months after HI, which is most likely due to the 
persisting prevalence of brain-antigen specific activated of T lymphocytes. Authors 
suggested the possibility, that the long-term adverse neurodevelopmental 




Albertsson et al. were the first who were able to describe the response of the 
different T helper subsets to HI in the brain and they found, that HI primarily elicited 
Th1/Th17-type immune response in the neonatal mice (326). They analyzed the 
expression of the characteristic cytokines and transcription factors of each Th subsets 
in the brain after HI injury with quantitative polymerase chain reaction (qPCR). They 
found that Th1-related (T-bet = T-box expressed in T cells, IL-12a) and Th17-related 
(RORγt = RAR-related orphan receptor C, IL-6, IL-23, and IL-22) genes were 
significantly upregulated 6-24 h after HI. IL-17A was however not detectable in the 
brain of neonatal mice. On the contrary the expression of Th2/Treg-related genes were 
either down-regulated (IL-4) or unchanged (GATA3, IL-5, Foxp3, TGFβ, and IL-10) 
in the acute phase following HI. This indicates, that HI elicits a robust immune 
response in the neonatal brain, which is characterized by an imbalance between pro-
inflammatory Th1/Th17- and anti-inflammatory Th2/Treg-type responses (326). 
Authors also suggested, that this imbalance in the type 1 and type 2 cytokine imbalance 
might be initiated early on, already by innate immune cells. Th1/Th17 predominance 
has been described in several neuroinflammatory conditions, such as periventricular 
leukomalacia (PVL) (327-329) and CNS inflammatory demyelination disease (330), 
and the inhibition of Th17-related cytokines reduced the extent of cerebral damage in 
a neonatal mouse model of HI (331). Furthermore, Th1 primed activated T-cells were 
also identified in peripheral blood after stroke (332), indicating, that the investigation 
of peripheral T cells subsets after HI is reasonable and important. 
Several studies support the hypothesis, that T lymphocytes play a pivotal role 
in maintaining the chronic immuno-inflammatory activation after perinatal HI. Some 
studies suggest, that adequate adaptive immune response is initiated after 7 days in 
mouse models, while others show a very early T cell response, however, all studies 
were able to show the presence and the activation of T lymphocytes in damaged areas 
until for at least a month after the initial injury (326, 333, 260, 257, 268). Effector T 
cells are able to exert neurotoxicity via several mechanisms  such as the production of 
perforin and granzyme B, the release of free radicals, the triggering of apoptotic 
pathways within neurons, and most importantly, the production of pro- and anti-
inflammatory cytokines (334, 335).  
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If T cells are depleted in the periphery by anti-CD3 or sphingosine-1-phosphate 
(S1P) receptor agonist, ischemia-induced neurodegeneration is ameliorated in adults. 
On the contrary, in neonates, peripheral T cell depletion leads to the exacerbation of 
hypoxic-ischemic brain injury. The reason behind this intriguing finding might be, that 
neonatal HI induces a more pronounced infiltration of Foxp3 positive regulatory T 
cells, and the inhibition of this process is most likely what leads to the detrimental 
consequences. However, T cell depletion lead to an increased infiltration of innate 
immune cells such as neutrophils and inflammatory macrophages, which could also 
aggravate the neuronal damage  (336). Liesz et al. aimed to characterize the role of 
CD4+CD25+ Foxp3+ Treg lymphocytes in hypoxic brain injury and found, that Treg 
depletion aggravated delayed brain damage and worsened functional outcome. In the 
absence of Treg cells, the activation of resident and invading inflammatory cells such 
as microglia and Foxp3-, effector T cells increased, along with levels of pro-
inflammatory cytokines such as TNF-α and IFN-γ. Substituting IL-10 suppressed the 
cytokine overexpression and prevented secondary infarct growth, indicating the 
essential role of IL-10 in the immunomodulatory effect of Treg (337). 
These data suggest, that certain neonatal T cell subsets also have important 
immunoregulatory functions after a hypoxic brain injury, which could provide new 
possibilities of therapeutic intervention. Altogether, even though the relevance of T 
cells in the development of perinatal hypoxic brain injury is becoming more and more 
clear, much less data is available on their functional alterations than on those of innate 
immune cells and human in vivo data is especially scarce. Such results could provide 
new insights into the course of neuroinflammation in neonates and reveal factors 
determining neurological outcome.  
2.4.3 ADHESION MOLECULES 
During neuroinflammation, adhesion molecules are key regulators of leukocyte 
recruitment and migration to the ischemic lesion. Cell adhesion molecules fall into 
three large groups of molecules: selectins, the immunoglobulin superfamily and 
integrins (338). Adhesion molecules present important therapeutic targets and several 
antibodies are already successfully used in clinical settings (257).  
One especially interesting adhesion molecule is the integrin very late antigen 
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(VLA)-4 (α4/β1, CD49d/CD29), which is responsible for the high-affinity binding of 
activated leukocytes and activated endothelial cells expressing vascular cell adhesion 
molecule (VCAM) -1 (339). CD49d is part of the VLA-4 antigen, which in the case of 
neuroinflammation, mediates the migration of activated lymphocytes through the BBB 
to the ischemic lesion (340, 341). Antibodies against CD49d have been successfully 
used in multiple sclerosis  to decrease disability progression and the rate of relapses 
(342), by inhibiting lymphocyte trafficking into the brain. The blocking of VLA-4 by 
antibodies was also shown to be protective 72 h after HI in adults and in murine 
ischemic stroke models (343, 232). Although VCAM-1 is generally expressed by 
inflamed endothelial cells and is not specific for the CNS, after a hypoxic brain insult, 
it will primarily be expressed in the vessels near the ischemic lesion. At the same time, 
the level of CD49d expression on T cells can be correlated with their capacity to enter 
the CNS (344). Even though they appear to be promising targets for modulating the T 
lymphocyte trafficking into the brain, the alterations of adhesion molecules in HIE are 
not well understood and experimental data is lacking. 
2.4.4 CYTOKINES 
The complex network of cytokines has been shown to play a crucial role in 
mediating the neuroinflammatory response triggered by HI and determining the extent 
of brain injury (345-347, 212, 348, 349). During neuroinflammation the primary 
source of cytokines are glial cells and immune cells, such as T helper cells (161). 
Cytokines are often categorized based on their effect as pro- or anti-inflammatory.  
Pro-inflammatory cytokines maintain the ongoing inflammation by inducing further 
cytokine release and continuous leukocyte migration, leading to the accumulation of 
neurotoxic agents (350). Pro-inflammatory cytokines have been implicated as 
mediators of both the early events and the latent, long-term neuroinflammatory 
response (161). TNF-α and IFN-γ have also been shown to be directly neurotoxic in 
vitro (347). Together with IL-1β, they appear to play a central role in the development 
of perinatal hypoxic brain injury (351-353), although IL-6, IL-8 and IL-17 are also 
likely to have an important contribution (354-357). On the other hand, anti-
inflammatory cytokines such as IL-4, IL-10, IL-11, IL-13 and TGFβ ameliorate the 
inflammation and TGF-β and IL-10 have been shown to be neuroprotective and crucial 
DOI:10.14753/SE.2020.2341
61 
for regenerative processes (1). 
However, the dual role of neuroinflammation following HI can already be 
recognized at level of the cytokine network, as apparently opposing effects of classical 
cytokines have been uncovered during the past decade. This might be explained by the 
fact, that cytokines, chemokines, and growth factors are ubiquitous signaling 
molecules and there is a significant overlap between the CNS and the immune system 
in the expression of these molecules (347).  In fact, T cells and other immune signals 
have been shown to play a role in adult hippocampal neurogenesis and spatial learning 
(358, 359). It also appears, that while excess amount of pro-inflammatory cytokines 
can aggravate neuronal injury, a certain level is essential for the fast elimination of 
cellular debris, neuronal growth and repair, and thus functional recovery (360, 302). 
The results of Saliba et al. also support the positive role of pro-inflammatory cytokines 
(i.e. TNF-α and IL-1) in neuronal regeneration (355). The effect and role of individual 
cytokines in perinatal hypoxic brain injury has been the highlight of the past decades’ 
research and the following pages will summarize some of these results. 
2.4.5 PRO-INFLAMMATORY CYTOKINES 
2.4.5.1 IL-1β 
IL-1β is a member of the IL-1 protein family and is an important mediator of 
inflammatory responses, cell proliferation, differentiation, and apoptosis. IL-1β is also 
one of the most important pro-inflammatory cytokines that have been associated with 
poor neurological outcome after HI injury (161). Many animal studies have 
demonstrated its role in both the early and the late stages of hypoxia-induced 
neuroinflammation (361-368). Upon hypoxic insult, IL-1β mRNA and protein levels 
are rapidly upregulated in the ipsilateral hemisphere of the neonatal brain and they 
remain elevated during the course of the neuroinflammatory response (369, 370, 297, 
371, 372). Continuously elevated IL-1β levels have been associated with permanent 
neuronal damage (373, 372). Although it appears, that IL-1β is not directly toxic to 
oligodendrocyte lineage cells, it does inhibit oligodendrocyte proliferation, which can 
delay white matter development and recovery (374). One of the main effects of IL-1β 
is the transcriptional activation of the iNOS gene (375) leading to NO generation (376, 
377), which is known to contribute to BBB breakdown and apoptotic neuronal death 
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(378, 368). Exogenous administration of IL-1β leads to the exacerbation of ischemic 
brain injury. Further supporting the relevance of IL-1β, it has been demonstrated that 
both the deficiency of the IL-1β converting enzyme and treatment with IL-1 receptor 
antagonists (IL-1ra) or blocking antibodies results in the moderation of the hypoxic 
brain injury (370, 379), decrease in the cellular edema (368), and improved 
neurological outcome (380). The beneficial effects of IL-1β down-regulation may be 
due to decreased microglial activation, leukocyte infiltration, and lower cytokine 
levels (370, 381, 382). 
There is however also some in vitro evidence, suggesting that IL-1β could have 
neurotrophic effects, exerted via the stimulation of nerve growth factor synthesis. 
Direct intracerebral injection of IL-1 or TNF-α have been shown to induce astrogliosis 
and angiogenesis in the developing rodent brain (383). 
The primary sources of IL-1β are APCs and monocytes (384, 385), although 
microglia and endothelial cells are also capable of producing IL-1β (386-388). 
However, the fact that T lymphocytes are able to produce physiologically relevant 
amounts of IL-1β and that it plays an important role in their functionality has only been 
recently revealed. Doitsh et al. were the first to describe functional IL-1β production 
in CD4 T lymphocytes in HIV infection (389), and Arbore et al. were able to 
demonstrate, that while APC-derived IL-1β supports initial T cell priming (390), 
proper imprinting of T helper effector function and maintenance of the Th1 phenotype 
during differentiation and migration into the periphery appears to rely on autocrine T-
cell derived IL-1β production (391). They also revealed, that the dysregulation of 
autocrine IL-1β mediated pathway leads to Th1-Th17 imbalance (389). Mice with 
deletion of IL-1β signal transducer are also unable to form memory T cells (392). 
Altogether, this indicates, that contrary to previous beliefs, T lymphocytes are capable 
of IL-1β production, in fact, it plays an indispensable role in the maintenance of their 
function. 
2.4.5.2 IL-6 
The understanding of the effects of IL-6 has changed over the past decade, as 
evidence emerged of its role in both pro- and anti-inflammatory processes. IL-6 has 
been demonstrated to exert both detrimental and neurotrophic effects in cerebral 
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ischemia, depending on the pathologic context (347). During neuroinflammation, IL-
6 is produced by astrocytes, possibly microglia and migrating immune cells such as 
monocytes and T lymphocytes (393). It has been suggested based on rodent models of 
HI, that IL-6 contributes to the exacerbation of the inflammatory response in the acute 
phase of hypoxic brain injury, and more to the neuronal regeneration in the secondary 
and tertiary phases (394). In line with this, the cerebral level of IL-6 shows a transient 
increase, and peaks hours after hypoxic injury, which has been associated with 
enhanced neuronal damage (370, 395). On the other hand, astrocyte-derived IL-6 has 
been shown to enhance neuronal survival and protect from NMDA receptor-mediated 
excitotoxicity after hypoxia-reoxygenation challenge in vitro (396, 397). The 
neuroprotective and neurotrophic effects of IL-6 might be mediated via leukemia 
inhibitory factor and ciliary neurotrophic factor (398, 399, 397, 161).  
2.4.5.3 IL-17 
IL-17 is a pro-inflammatory cytokine often associated with detrimental 
consequences in inflammatory diseases. It is primarily produced by a subset of T 
lymphocytes upon IL-23 stimulation, called Th17 cells (400), although other cells 
types, such as CD8+ T cells are also capable of producing IL-17 (401). IL-17 also 
appears to be involved in the late stages of neuroinflammation, playing a role in the 
delayed progression of brain infarction. In an experimental ischemic stroke model, the 
size of the infarcted area was significantly reduced in IL-17KO mice from the 4th post-
stroke day onwards, accompanied by decreased apoptotic neuronal death (402).  
It appears, that Th17 response could also be an important link between systemic 
inflammation and aggravated hypoxic-ischemic CNS injury. IL-23R and IL-17 levels 
were higher both in rat pups challenged by LPS-sensitization and infants with a history 
of chorioamnionitis who sustained HI brain injury. The blocking of lymphocyte 
trafficking to the CNS by sphingosine-1-phosphate receptor (S1PR) agonist resulted 
in decreased CNS CD4+ and IL-17+ cell count and rescued up to 90% of LPS/HI-
induced brain tissue loss in a dose-dependent manner in mice. However, it did not 
affect tissue loss due to “pure” HI injury, highlighting its efficacy in inflammation-
sensitized HI injury. This indicates, that Th17-mediated immunity could play a critical 
role in the development of perinatal hypoxic brain injury following exposure  to 
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inflammation (284, 403).  
2.4.5.4 IFN-γ 
IFN-γ is another classical Th1-type, pro-inflammatory cytokine which has been 
demonstrated to prompt neuronal development. IFN-γ has also been suggested to play 
a dual role in HI brain injury. Data indicates, that depending on the timing and level of 
expression, IFN-γ could have destructive and protective effects in the brain (161). IFN-
γ is an important mediator of Th1-type cellular immune responses and is produced in 
large amounts by Th1 cells, although reactive microglial cells, macrophages and 
astrocytes are also important sources in the early stages of neuroinflammation. IFN-γ 
drives further Th1 differentiation and the production of pro-inflammatory cytokines, 
such as TNF-α (404). Its molecular effects include ROS production and lipid 
peroxidation, which add to its neurotoxicity (328). However, the contribution of IFN-
γ to neuronal survival, differentiation, ramification, and myelin formation has also 
been demonstrated. Experimental data even suggests, that IFN-γ could act as a 
neuroprotective agent by decreasing the apoptosis of oligodendrocyte progenitors 
(405) and astrocytes (406) in rodent models of HI. Elevated levels of IFN-γ were 
observed in the cord blood of neonates with white matter injury in the first 72 hours of 
life (328, 407). However, the role and contribution of IFN-γ to the development of 
perinatal HI brain injury is not clear and experimental data is lacking (161).  
2.4.5.5 TNF-α 
The data published, that supports the role of TNF-α in the development of 
ischemic brain damage is surmounting (408, 370, 409, 410, 395). TNF-α has also been 
suggested to play a role in perinatal stroke, however further studies are necessary to 
assess its role. TNF-α is a classical pro-inflammatory cytokine, that stimulates the 
production of IL-1β and other cytokines, promotes leukocyte differentiation, 
proliferation and CNS infiltration (411, 412). On the other hand, TNF-α also plays a 
role in neuronal progenitor cell proliferation, lineage commitment and cellular 
differentiation. Direct intracerebral injection of IL-1 or TNF-α has been shown to 
stimulate astrogliosis and angiogenesis in the developing rodent brain (284, 383).  
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TNF-α binds to two different receptors, that activate distinct signaling 
pathways. On the one hand, excess amounts of TNF-α may induce apoptosis via TNF-
R1 (413), on the other hand binding to TNF-R2 can prompt cell survival, growth and 
proliferation (414). Exposure to TNF-α reduced oligodendrocyte progenitor survival 
and maturation in vitro and led to reduced myelination (415, 405, 161). TNF-α induced 
apoptosis in both developing and mature oligodendrocytes (416, 417). In vivo, after 
HI insult, oligodendrocytes expressed higher levels of TNF-R1, which could explain 
the higher rate of apoptosis and the delayed demyelination (362, 418). TNF-α 
expression began to increase early and peaked 6-12 hours following hypoxic ischemic 
injury in newborn rats, indicating its role in the early events of neuroinflammation 
(419).  Higher TNF-α and IL-1β plasma and CSF levels in term neonates with perinatal 
HIE have been associated with worse neurological status at 12 months of age and 
higher incidence of cerebral palsy (420, 421). Upon inhibition of TNF-α by 
pentoxifylline, a competitive inhibitor, neurological outcome improved. Blocking 
TNF-α resulted in reduced BBB disruption and also protected neurons from delayed 
cell death in animal models of head trauma (422).  
2.4.6 ANTI-INFLAMMATORY CYTOKINES 
2.4.6.1 IL-10 
IL-10 is a classic anti-inflammatory cytokine, mostly produced by Tregs and 
activated monocytes and macrophages. Its anti-inflammatory effects are exerted by the 
down-regulation of the activation and cytokine production of microglia and 
macrophages (406). The cerebral level of IL-10 shows a significant increase after HI 
(369, 161). In vitro data shows, that IL-10 is able to exert neuroprotective effects 
decreasing hypoxia-induced neuronal death and LPS- or IFN-induced oligodendrocyte 
loss (423-425). IL-10 has also been shown to neutralize the metabolic and 
microcirculatory effects of perinatal HI in piglets (426).  
However, in vivo a neuroprotective effect could only be observed, if IL-10 was 
administered exogenously following HI. Neither IL-10 blocking antibodies or IL-10 
KO had any effect on the size of the brain lesion, indicating that endogenous IL-10 
appears to have a lesser role in moderating the neuroinflammatory response. IL-10 
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administration was however able to counteract the deleterious effects of pro-
inflammatory cytokines IL-1β and IL-9, suggesting, that exogenous IL-10 can exert 
neuroprotective effects in an inflammatory context  (406). In one clinical observational 
study, preterm neonates who were found homozygous for the high IL-10 producer - 
1082 G-allele were significantly less likely to develop periventricular lesions (427). 
2.4.6.2 TGF-β 
The TGF-β family consists of pleiotropic proteins with potent 
immunoregulatory properties, which are also important regulators of the development, 
repair and survival of neurons (355). The most important immunosuppressive effects 
of TGF-β are the direct inhibition of inflammatory cells and the promotion of Treg 
function by inducing their Foxp3 expression (428-434). Activated Tregs then produce 
large amounts of TGF-β, which maintains the immunosuppressive milieu (435). TGF-
β specifically limits Th1 differentiation and expansion (436, 437) without altering Th2 
effector function. It also suppresses the production of pro-inflammatory cytokines, 
while promoting the production of anti-inflammatory IL-10 (438). In addition to direct 
inhibition, Tregs also inhibit T cell function by interfering with the APC - T cell 
interactions, for example by activating the cytotoxic T lymphocyte antigen - 4 (CTLA-
4) pathway, which induces tryptophan (TRP) catabolism by indoleamine 2,3-
dioxygenase (IDO) (284, 439, 440).  
An increasing body of evidence supports the neuroprotective effect of TGF-β 
in HI brain injury (441). The induction of TGF-β1 synthesis reduced the size of the 
infarcted area in rats (442). Exogenously administered TGF-β was also effective in 
reducing infarct volume in several animal models (443-445). One study showed, that 
direct cerebral administration of TGF-β improved short-term neurological function 
after HI injury adult rats, however, it did not have a long-term neuroprotective effect 
(347, 446). One clinically especially relevant finding is that non-invasive, intranasal 
TGF-β administration was also effective in reducing the affected area and improving 
functional recovery in mice (447). On the other hand, TGF-β -inhibition lead to 
exacerbated HI brain injury, demonstrating the neuroprotective value of endogenous 
TGF-β production (441, 448).  
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2.4.7 THE KYNURENINE SYSTEM 
The interplay between the cytokine network and the kynurenine system 
regulates both innate and adaptive immune responses, and is also important in the 
bidirectional relationship of the central nervous system and the immune system (449, 
450). IDO is an inducible enzyme, which catalyzes the first, rate-limiting step of TRP 
catabolism. It is a key mediator of neuroimmune interactions. IDO degrades TRP to 
kynurenine (KYN), which is then metabolized by the enzymes of the kynurenine 
pathway into further catabolites, such as kynurenic acid (KYNA). Certain TRP 
metabolites can exert neurotoxic properties, however, the primary metabolite, KYNA 
has been shown to have neuroprotective effects. In vitro KYNA ameliorates NMDA 
receptor-mediated excitotoxicity in the human neocortex (451), exhibits high free 
radical scavenging activity and is an endogenous inhibitor of oxidative stress (452).  
IDO is mainly produced by APCs and is a potent immunosuppressive agent. It 
is induced by pro-inflammatory signals (such as IFN-γ), and its most important 
function is the maintenance of the immunobalance. Tryptophan depletion renders 
effector T cells inactive and APCs immunosuppressive (453). IDO induction and the 
activation of the kynurenine pathway also leads to the activation of regulatory T cells 
and the inhibition of natural killer cells. The rate of TRP degradation can be measured 
by the ratio of KYN to TRP (K/T), which allows close estimation of the enzymatic 
activity of IDO (454). The alterations of the kynurenine system appear to be important 
in the pathophysiology of a broad spectrum of neurological disorders (455), however 






3 STUDY RATIONALE 
The neuroinflammatory response, which is a common consequence of HI brain 
injury, appears to have two sides. A certain level of inflammation is part of the 
physiological response to any injury and is essential in reparative processes of the 
infarcted tissue (282). However, there is substantial evidence demonstrating the 
detrimental consequences of excessive neuroinflammation, leading to exacerbated 
CNS injury and worse neurological outcome.  
In this study one of our primary focuses was to determine which aspects of the 
neuroinflammatory response could differ between neonates with moderate HIE, who 
are likely to have normal neurodevelopmental outcome or mild disability and neonates 
with severe HIE who are likely to have poor outcome (death or severe disability). We 
focused on characterizing the components of the adaptive immune system, more 
specifically T lymphocytes, since there is little in vivo data available regarding the 
alterations of T cells during perinatal HI brain injury.  
The majority of previous studies performed on samples from neonates with 
HIE focused on determining the plasma cytokine levels, which raises many concerns. 
Plasma cytokine levels are secreted by a wide variety of innate and adaptive immune 
cells, and it is therefore difficult to comment on their specific local role in the CNS. 
As previously described, cytokines are capable of exerting even opposing effects 
depending on the milieu. Furthermore, the diffusion of cytokines from the plasma to 
the inflammatory focus (in HI injury the CNS) is marginal compared to the local 
production. It is possible however, that specific immune cells which are active at the 
inflammatory focus are present in the peripheral circulation. Therefore, by 
characterizing specific cellular subsets it is possible to gain a more precise 
understanding of events during an inflammatory process. Another consideration is, that 
plasma cytokine levels show larger variability and are less stable over time, than 
intracellular cytokines, which remain within the observed cells until the time of 
measurement and thus more closely reflect the cytokine production at a cellular level 
(456, 457). Due to these reasons we primarily focused on the intracellular cytokine 
production of T lymphocytes, however we also measured plasma cytokine levels to try 
to form a more comprehensive overview of the immunological alterations following 
perinatal HI injury.  
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Due to the high level of ubiquity in the cytokine network, it is hard to identify 
a single factor, which determines long-term outcome, even more so, because the effect 
of cytokines is highly dependent on the context (type of insult, timing) (347). However, 
certain cytokine profiles have been associated with detrimental consequences (161), 
and current research is focused on identifying these key inflammatory signatures. The 
real goal would be to distinguish between the level of inflammation necessary for CNS 
regeneration and the characteristics of inflammation which lead to poor outcome.  
There is also emerging evidence indicating, that perinatal HI injury could be 
followed by an extended period of chronic neuroinflammation, which could alter many 
aspects of neurodevelopment and contribute to the long-term consequences of 
perinatal HI injury. Although there are emerging studies on the long-term effects of 
neuroinflammation on neurodevelopment, the majority of these data are 
circumstantial, and little is known about the events of this phase of the 
neuroinflammatory response in humans. Therefore, we extended our observation 
period to the whole first month of life to try to gain a better understanding of the 
tertiary, chronic phase of the neuroinflammatory process. Such data from human 
samples have not been published previously. Gaining a better understanding of the 
long-term effects of perinatal HI brain injury could open novel opportunities for 





In this study our aims were the following: 
1. To assess the differences in the prevalence and cytokine production of T 
lymphocyte subsets between moderate and severe HIE, in order to identify the 
players of the inflammatory response that may influence the severity of the 
neuroinflammation 
2. To assess the alterations of plasma cytokine levels in comparison with 
intracellular cytokine levels in moderate and severe HIE 
3. To describe the plasma levels of the substances of the kynurenine system (TRP, 
KYN and KYNA) and assess IDO activity based on the KYN/TRP ratio in 
moderate and severe HIE 
4. Based on the pooled data collected in the first month of life from four NAIS 
patients, we aimed to assess the gross differences in the cytokine production of 
T lymphocytes and plasma cytokine levels between moderate, severe HIE and 
NAIS. Similar data has not been published in humans before, therefore, 
although the number of NAIS cases is small, the presented data could serve as 





5 MATERIALS AND METHODS 
5.1 PATIENTS 
We enrolled 33 term neonates in our study, all of whom were outborn and 
admitted to the regional neonatal intensive care unit at the First Department of 
Pediatrics at Semmelweis University, Budapest, Hungary with the initial diagnosis of 
perinatal asphyxia. The diagnosis of moderate-to-severe hypoxic-ischemic 
encephalopathy and the eligibility for cooling were assessed according to the TOBY 
criteria (88). Neonates, who had congenital abnormalities, CNS malformations or were 
born from mothers who had signs of chorioamnionitis were not included in the study. 
All enrolled neonates met the criteria for therapeutic total body hypothermia, which 
was initiated upon admission, between 1-5 hours of life. During the 72-hour 
hypothermia period, the rectal temperature of neonates was recorded every hour and 
maintained between 33-34 °C. Clinical characteristics and laboratory parameters of 
participants are summarized in Table 4. 
Study-related blood sampling was adjusted to clinical care, 2x1 ml of 
peripheral venous blood was collected together with blood samples necessary for 
clinical care. Samples were collected on 5 occasions from each neonate: between 3-6 
hours of life (at admission), at 24 hours, at 72 hours and at 1 week of life during the 
intensive care treatment and at 1 month of age during a routine outpatient follow-up 
appointment. Samples were processed within 6 hours in all cases, samples were not 
cooled during this period. 
Upon admission blood cultures and ear swabs were obtained from all neonates 
to exclude perinatal bacterial infection. All neonates received prophylactic intravenous 
antibiotic treatment (ampicillin-gentamycin) in the first days of life, which were 
stopped after negative blood cultures were received. Infants were monitored for 
infection during the first month of life, clinical or culture-proven sepsis was not 
detected in any participants. Neonates received standard intensive care, during the 
study period 13 neonates required inotropic therapy and 10 neonates required 
hydrocortisone as additional blood pressure supportive therapy, 3 neonates required L-
thyroxin-supplementation due to low fT4 serum levels, 12 neonates received red-
blood-cell concentrate on at least one occasion due to anemia, 3 neonates received 
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platelet concentrate due to low platelet count (< 100G/l) and 16 infants received at 
least one dose of fresh-frozen-plasma due to coagulopathy. 
Neonates were monitored by aEEG and MRI examinations were performed 
within the first week of life if possible, and within 12 days of life in all cases. MRI 
data were interpreted by radiologists who were blinded to the clinical status of the 
neonates, based on criteria defined by Rutherford et al. (458, 30). Based on the MRI 
scan results, four neonates were diagnosed with neonatal arterial ischemic stroke. 
These cases are presented in detail below. One neonate was excluded from the study 
due to metabolic disease (peroxisomal fatty acid C26/C22 ratio was above the normal 
range) along with the presence of multiple minor anomalies and the mutation of the 
ROBO1 gene. The other 28 neonates were divided into two groups (moderate and 
severe HIE) depending on the severity of hypoxic-ischemic encephalopathy, which 
was determined based on the initial status and the time of normalization of the aEEG 
recordings (459) and the MRI scan results. A structured MRI reporting template was 
developed by a collaborating research group in the ISORT (intelligent structured 
online reporting tool) software framework created by Bioscreen Ltd., Debrecen, 
Hungary based on the work of Marcovici et al. and Bosmans et al. (460, 461).  
 
The severe group (n = 11) was constituted of neonates who: 
A. Had signs of moderate-to-severe HIE on the MRI scans AND 
B. Met at least one of the following criteria: 
I. Had signs of moderate-to-severe HIE on the aEEG, defined as:  
i. burst-suppression  
ii. continuous extremely low voltage background activity 
iii. flat tracing background activity 
II. The normalization of the aEEG activity occurred after 48 hours of life 
or never 




The moderate group (n = 17) was constituted of neonates, who  
A. Met none of the above listed criteria, AND  
B. Had normal MRI scans or mild signs of HIE on the MRI scans, AND  
C. Their aEEG recordings met at least one of the following criteria: 
I. Normal voltage background activity  
II. Normalization of aEEG activity occurred before 48 hours of life. 
 
Table 4. Clinical characteristics of included neonates. The initial laboratory results 
are presented, which were collected upon admission (within 12 h of age). 
Data are presented as median (IQR). Data were compared with Mann-Whitney tests.  




(n = 17) 
Severe HIE 
(n = 11) 
NAIS 
(n = 4) 
Clinical characteristics 















No. of C-sections 
(%) 
10 (59%) 8 (73%) 3 (75%) 





















































In the severe group, 3 infants deceased before one month of age due to the 
severity of the HI insult. In these cases, the MRI examination could not be performed 
due to the critical condition or early death of the patient, therefore these cases were 
included in the severe group based on the aEEG results and the poor putcome. Data, 
which were available from these neonates were included at respective time points. 
Overall, 72 hour, 1 week and 1 month data were missing from 2 infants and only 1 
month data were missing from 1 infant. Pooled data from the cohort of 4 NAIS patients 
were compared to neonates with HIE.  
Our study was reviewed and approved by the Hungarian Medical Research 
Council (TUKEB 6578-0/2011-EKU) and written informed consent was obtained 
from parents of all participants. The study was adhered to the tenets of the most recent 
revision of the Declaration of Helsinki. The data and protocols presented here have 
been published (233, 284). 
5.2 NAIS CASE PRESENTATIONS 
5.2.1 CASE 1. 
The neonate was delivered by an emergency caesarean section due to 
oligohydramnios and fetal tachycardia on the 40th week of gestation, following an 
uncomplicated pregnancy. The mother had no history of chronic illnesses, no signs of 
maternal chorioamnionitis were present, however it should be noted, that the mother 
smoked during her pregnancy. The amniotic fluid was stained with thick meconium, 
and the Apgar score was 5/6/7. The neonate had to be resuscitated after delivery and 
required intubation and assisted ventilation in the first days of life. The first capillary 
blood gas showed deep acidosis (pH 7.03, BE -14 mmol/L, lactate 12.4 mmol/L) and 
she soon became irritable, her general muscle tone increased, thus, hypothermic 
treatment was initiated. On the second day of life she presented with symptoms 
characteristic of pulmonary hypertension, which resolved after one day of NO 
inhalation and she was extubated on Day 3 of life. Her early neurodevelopmental 
examination showed mild central hypotonia. 
Cranial MRI with diffusion-weighted imaging was performed on Day 4, and 
showed a distinct, 5x7 mm ischemic area with decreased diffusion in the left thalamus 
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and no evidence of bleeding. MR spectroscopy showed a decrease in metabolites, 
characteristic of slight general hypoxia-ischemia. 
5.2.2 CASE 2.  
The neonate was delivered by an emergency caesarean section due to complete 
placental abruption on the 39th week of gestation with an Apgar score of 3/5/8. The 
mother had no history of any illnesses. At birth no respiratory effort was present, and 
the neonate was hypotonic and pale, but had a heartrate of 80/min. After short bag and 
mask ventilation, his heartrate normalized, but only gasping was present, thus he was 
intubated. The neonate soon began to show signs of neurological involvement, such as 
irritability. The first blood gas showed severe metabolic acidosis (pH 6.99, BE -14), 
therefore hypothermic treatment was initiated. A chest X-ray was performed due to 
ventilation difficulty, which showed a pneumothorax on the right side, which was 
drained. The neonate required blood transfusion on two occasions due to severe 
anemia and low blood pressure, and inotropic support for six days. An early 
neurodevelopmental examination indicated grossly abnormal central and peripheral 
tone distribution.  
Cranial MRI was performed on Day 4 of life. Diffusion-weighted imaging 
showed a large area of ischemia with decreased diffusion in the area of the left middle 
cerebral artery, and several smaller lesions in the area of the right middle cerebral 
artery. No signs of bleeding were present. Time-of-flight (TOF) MR angiography 
showed marked irregularity and significantly decreased blood flow in both MCAs, but 
especially on the left side. No signs of hypoxic-ischemic encephalopathy were present 
on the MRI scan.  
5.2.3 CASE 3.  
The neonate was born by a normal vaginal delivery on the 40th week of 
gestation, following an uncomplicated pregnancy with an Apgar score of 5/5. The 
neonate was hypotonic, and spontaneous breathing was not initiated after birth, 
therefore she was intubated. The first gasping breaths were observed at 15 minutes 
after birth, but the neonate remained hypotonic. The first blood gas showed severe 
acidosis (pH 6.89, BE -18 mmol/L, lactate 15 mmol/L). Therapeutic hypothermia was 
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initiated. The initial aEEG recordings showed abnormal background activity, the 
normalization occurred within a few hours. The early neurodevelopmental 
examination reported moderate generalized hypotonia. 
The cranial MRI examination was performed on Day 3 of life. Diffusion-
weighted imaging showed a small (3 mm) ischemic lesion in the right thalamus. 
Further ischemic areas, bleeding or signs of hypoxic ischemic encephalopathy were 
not present. 
5.2.4 CASE 4.  
The neonate was born by emergency caesarean section following an 
uncomplicated pregnancy on the 38th week of gestation due to fetal distress. His Apgar 
score was 3/6/7, he was flaccid with no spontaneous breathing and a heart rate of 
80/min. After bag and mask ventilation spontaneous breathing was noted at 5 minutes, 
but the neonate remained hypotensive and areflexive, therefore he was intubated. The 
initial blood gas showed severe acidosis (pH 6.875, BE -14). Therapeutic hypothermia 
was initiated. The initial aEEG recording showed no signs of seizures. The early 
neurodevelopmental examination indicated abnormal central and peripheral tone 
distribution.  
Cranial MRI was performed early, on the first day of life. Diffusion-weighted 
imaging showed decreased diffusion indicating ischemia in the area of the right 
posterior cerebral artery. Smaller lesions were present in the right thalamus and the left 
parieto-occipital area. No signs of bleeding or hypoxic ischemic encephalopathy could 
be observed.  




5.3 SUMMARY OF MEASURED PARAMETERS 
 
Table 5. Overview of all measured parameters and the methods used. 
For flow cytometry, all measurements were done on whole blood samples where red 
blood cells were lysed. Intracellular cytokine levels were evaluated within each subset, 
identified by labelling characteristic cell-surface markers. Immunoassays and High-
performance liquid chromatography (HPLC) measurements were performed from 
plasma samples.  
 
 Associated cell subsets Place of 
measurement 
Method  
Cell surface markers 
CD4 T helper lymphocytes (Th) Cell surface Flow cytometry 
CD8 Cytotoxic T lymphocytes 
(CTL) 
Cell surface Flow cytometry 
CD49d Extravasation marker  
(i. e. to the CNS) 
Cell surface Flow cytometry 
Pro-inflammatory factors 
IL-1β Macrophages, smaller 
amount produced by T cells 
Intracellular  Flow cytometry 
Plasma Immunoassay 
IL-2 Main T cell activation factor, 
high amounts by Th1  
Plasma Immunoassay 
IL-6 Th17 cells, also exerts anti-
inflammatory properties 
Intracellular  Flow cytometry 
Plasma Immunoassay 
IL-7 Stromal cells, dendritic cells, 
for lymphocyte development 
Plasma Immunoassay 
IL-8 Macrophages, known as 
neutrophil chemotactic factor 
Plasma Immunoassay 
IL-12 Th1 cells  
(differentiation signal) 
Plasma Immunoassay 
IL-17 Th17 cells (CD4+) and  
Tc17 cells (CD8+) 
Intracellular  Flow cytometry 
Plasma Immunoassay 
IFN-γ Th1 cells, smaller amounts in 
CTL 




G-CSF Endothelium, macrophages, 
neutrophil maturation 
Plasma Immunoassay 
MCP-1 Monocyte chemoattractant 
protein (chemokine) 
Plasma Immunoassay 
MIP-1β Macrophage inflammatory 
protein (chemokine) 
Plasma Immunoassay 
TNF-α Macrophages, Th 
lymphocytes 
Intracellular  Flow cytometry 
Plasma Immunoassay 
VCAM Vascular adhesion of immune 
cells to endothelium 
Plasma Immunoassay 
Anti-inflammatory factors 
IL-4 Th2 cells  
(differentiation signal) 
Plasma Immunoassay 
IL-5 Th2 cells Plasma Immunoassay 
IL-10 Treg cells Intracellular  Flow cytometry 
Plasma Immunoassay 
IL-13 Th2 cells Plasma Immunoassay 
Foxp3 Key transcription factor of 
Treg cells 
Intracellular  Flow cytometry 
GM-CSF Treg, both pro- and anti-
inflammatory effects 
Plasma Immunoassay 
TGF-β Treg Intracellular  Flow cytometry 
Plasma Immunoassay 
KYN Ubiquitous Plasma HPLC 
KYNA Ubiquitous  Plasma HPLC 





5.4 FLOW CYTOMETRY 
The 2 ml-s of peripheral blood samples were centrifuged to separate plasma, 
plasma samples were aliquoted and immediately frozen at -80 °C for later 
determination of plasma cytokine concentrations and HPLC measurements (see 
below). An overview of all measured parameters are provided in Table 5. 
The remaining fraction was resuspended in RPMI (Roswell Park Memorial 
Institute-1640 medium, Sigma-Aldrich, St. Louis, MO, USA) to 2 ml end volume. 
Samples were incubated with PMA (Phorbol 12-myristate 13-acetate) (50 ng/ml), 
ionomycin (1 microg/ml) and BFA (Brefeldin A) (10 microg/ml) for 6 h at 37 °C to 
allow intracellular accumulation of cytokines.  
After 6 hours, samples were washed, divided into four equal aliquots:  
• P1+: for labeling of the cytokines of Panel 1 
• P1-: for the isotype controls of cytokines in Panel 1 
• P2+: for labeling of the cytokines of Panel 2 
• P2-: for the isotype controls of cytokines in Panel 2 
Cell surface markers were labeled with the following fluorochrome-conjugated 
anti-human monoclonal antibodies according to the manufacturers’ instructions: CD4 
PE-Cy7 (Phycoerythrin-Cyanine 7) and CD8 APC-Cy7 (Allophycocyanin-Cyanine 7) 
in Panel 1, or CD4 APC-Cy7 and CD49d PerCP (Peridinin-Chlorophyll-Protein) in 
P2+ tube and only CD4 APC-Cy7 in P2- tube (all from BioLegend, San Diego, CA, 
USA). Tubes were incubated for 30 minutes at room temperature.  
Red blood cells were then lysed and PBMCs were permeabilized using 
FACSLysing and FACSPermeabilizing solutions according to manufacturer’s 
instructions (BD Biosciences, San Jose, CA, USA). 1 ml of 1x FACS Lysing solution 
was added to each tube, after gentle vortexing, tubes were incubated for 20 minutes at 
room temperature. Cells were then washed, centrifuged and resuspended in 500 µl of 
1x FACS Permeabilizing solution. Tubes were incubated for 10 minutes at room 
temperature.  
Cells were washed, centrifuged and resuspended in PBS (phosphate buffer 
saline) for intracellular staining using isotype controls. The following conjugated anti-
human monoclonal antibodies or the appropriate isotype controls were applied 
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according to the manufacturers’ instruction: IL-6 PE (Phycoerythrin), IL-17A PerCP 
(Peridinin Chlorophyll Protein Complex), IL-10 APC (Allophycocyanin), IFN-γ FITC 
(Fluorescein Isothiocyanate) (for Panel 1), or TNF-α PE-Cy7, Foxp3 PE, TGF-β APC, 
IL-1β FITC (for Panel 2), all from BioLegend. Samples were incubated for 30 minutes 
at room temperature.  
After intracellular labeling, cells were washed and resuspended in 300 µl of 
PBS for analysis by flow cytometry. Samples were measured immediately on a 
FACSAria flow cytometer (BD Biosciences) equipped with 488 and 633 nanometer 
excitation lasers and FACSDiVa software (BD Biosciences). 100,000 cells were 
recorded. Gating and analysis was performed using FlowJo, LLC (284).  
5.5 IMMUNOASSAYS 
Plasma samples were stored at -80 °C until analysis. The plasma levels of the following 
cytokines, chemokines and growth factors were measured using Bio-Plex Pro Assays 
(Bio-Rad Laboratories, Hercules, CA, USA): IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-10, IL-12, IL-13, IL-17, IFN-γ, TNF-α, TGF-β, G-CSF, GM-CSF, MCP-1, MIP-
1β and VCAM. Bio-Plex Pro Assays are immunoassays similar to a sandwich ELISA. 
Capture antibodies against the biomarker of interest are covalently coupled to 
magnetic beads. A biotinylated detection antibody creates the sandwich complex and 
the final detection complex is formed by the addition of a streptavidin-phycoerythrin 
(SA-PE) conjugate, where PE serves as the fluorescent reporter. Reactions are read 
using a Luminex-based reader (284). 
5.6 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
(HPLC) 
Plasma samples were stored at -80 °C until analysis. Directly prior to analysis, samples 
were thawed, vortexed and 300 µl of plasma was “shot” onto 700 µl of precipitation 
solvent (containing 3.57 w/w% perchloric acid and 2.857 mM 3-nitro-L-tyrosine as 
internal standard (Scharlau, Barcelona, Spain)). Samples were then centrifuged (13000 
G for 10 minutes at 4 °C) and the supernatants were collected. For the quantification 
of KYN, KYNA, and TRP concentrations of samples, a modified method was used 
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based on the work of Herve et al. (462), using an Agilent 1100 HPLC system (Agilent 
Technologies, Santa Clara, CA, USA). The system was equipped with a fluorescent 
detector, by which the concentration of KYNA and TRP was determined, and a UV 
detector, by which the concentration of KYN and the internal standard was determined. 
Chromatographic separations were performed on an Onyx Monolithic C18 column, 
100 mm × 4.6 mm I.D. (Phenomenex Inc., Torrance, CA, USA) after passage through 
a Hypersil ODS precolumn, 20 × 2.1 mm I.D., 5 µm particle size (Agilent 
Technologies) with a mobile phase composition of 0.2 M zinc acetate/acetonitrile 95/5 
v/v% with a pH adjusted to 6.2 with glacial acetic acid, applying isocratic elution. The 
flow rate and the injection volume were 1.5 ml/minute and 20 µl, respectively. The 
fluorescent detector was set at excitation and emission wavelengths of 344 nm and 398 
nm respectively, and after 3.5 minutes of each run, the wavelengths were changed to 
254 nm and 398 nm. The UV detector was set at a wavelength of 365 nm. L-TRP, L-
KYN sulfate salt, KYNA and zinc acetate dihydrate were purchased from Sigma-
Aldrich and acetic acid was purchased from VWR International (Radnar, PA, USA) 
(284). 
5.7 STATISTICAL ANALYSIS 
First, test of normality was performed (according to Kolmogorov-Smirnoff), 
which indicated non-normal distribution of data. Therefore, Mann-Whitney tests were 
used to make comparisons between two different sample populations. For comparisons 
between the paired values (samples collected at different time points from the same 
patients) within the same population, Friedman test was used. Outliers were identified 
using Grubbs’ tests and were excluded from analyses. Data are expressed as median 
and interquartile range, p values less than 0.05 were considered significant. For 
statistical analysis and calculations, the GraphPad Prism 5 software (La Jolla, CA, 





We found significant alterations in both the prevalence of T lymphocytes 
expressing certain cytokines, the intracellular level of cytokines and the plasma levels 
of cytokines between our study groups. The main focus of our study, the differences 
between moderate and severe HIE will be presented first. Differences between NAIS 
and HIE groups will be shown later. Pro- and anti-inflammatory factors will be 
presented separately.  
To create a systematic way of presenting our data, the following method of 
showing significant differences is used in all tables and figures. To present differences 
between two study populations, stars are used: * if the data is different compared to 
moderate HIE at the same time point, and ** if the data is different compared to severe 
HIE at the same time point. To present differences between different time points within 
the same study population letters are used in the following manner: “a” if the difference 
is significant compared to the 6 h value, “b” if the difference is significant compared 
to the 24 h value, “c” if the difference is significant compared to the 72 h value and 




6.1 COMPARISONS BETWEEN THE MODERATE AND THE 
SEVERE HIE GROUPS 
6.1.1 PRO-INFLAMMATORY CYTOKINES 
Table 6. Differences in pro-inflammatory cytokines between moderate and severe 
HIE groups. The prevalence of T cells expressing certain cytokines are shown as the 
percentage of the parent population. The intracellular levels of cytokines are shown 
by the mean fluorescence intensity (MFI) of each cytokine within the subset of T cells 
in arbitrary unit. Plasma cytokine levels are shown in pg/ml. Data are expressed as 
median (IQR). Only significant alterations are shown, p ≤ 0.05 in all cases.  
 
Time Moderate HIE 
(n = 17) 
Severe HIE 
(n = 11) 
Cell prevalence data (% of parent population) 
CD4+ IL-1β+/CD4+ 6 h 3.52 (2.13-5.16) 6.77 (3.18-10.26) 
CD4+ IL-1β+ CD49d+/ 
CD4+ IL-1β+ 
6 h 6.98 (4.61-9.32) 4.08 (2.86-5.46) 
CD4+ TNF-α+ CD49d+/ 
CD4+ TNF-α+ 
6 h 6.63 (4.47-13.45) 3.52 (2.12-7.23) 
CD8+ IL-17+/CD8+ 6 h 5.26 (3.89-14.40) 2.30 (1.73-4.49) 
CD4+ TNF-α+ CD49d+/ 
CD4+ TNF-α+ 
72 h 4.77 (3.43-7.70) 9.75 (6.31-10.80) 
CD4+ IL-17+/CD4+ 1 wk 3.08 (1.80-4.59) 5.13 (3.40-13.76) 
Intracellular cytokine levels - MFI data (arbitrary unit) 
IL-17 / CD8+ 24 h 1069 (639-3265) 4187 (1274-6133) 
IFN-γ / CD4+ 72 h 455 (150-770) 887 (496-1427) 
IL-17 / CD4+ 72 h 939 (566-1674) 1760 (1614-3508) 
TNF-α / CD4+ 1 mo 3281 (1752-4326) 4729 (3959-6714) 
Plasma cytokines (pg/ml) 
G-CSF 24 h 19.85 (10.87-30.70) 42.74 (22.27-131.3) 
G-CSF 1 wk 13.33 (5.52-17.72) 32.90 (16.65-94.76) 




We found an elevated prevalence of IL-1β-expressing CD4 lymphocytes at 6 h 
after birth in severe HIE compared to moderate HIE. These cells also showed a higher 
rate of extravasation to the CNS at 6 h in severe HIE, indicated by the decrease in the 
prevalence of CD49d-expressing CD4+ IL-1β+ cells in the peripheral blood (Table 6). 
The prevalence of these cells did not differ at later time points. 
 
Figure 10. Alterations in the intracellular IL-1β level of CD4+ lymphocytes and 
plasma IL-1β levels during the first month of life within the moderate and severe 
HIE. Intracellular level is shown by the MFI of IL-1β. Plasma IL-1β level is shown in 
pg/ml. Moderate HIE (n = 17), severe HIE (n = 11). Horizontal line: median, box: 
interquartile range, whisker: range. p ≤ 0.05 a vs 6 h (all within the same group). 
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However, the intracellular levels of IL-1β, indicated by the mean fluorescence 
intensity (MFI) of IL-1β were similar in the two study groups, the peak was at 6 h and 
intracellular IL-1β levels were comparably lower at the following time points. The 
plasma levels of IL-1β changed similarly in the moderate HIE, and showed a similar 
tendency in the severe group, but did not reach the level of significance (Figure 10). 
No differences were present in the plasma level of IL-1β between moderate and severe 
HIE. These data support the role of IL-1β in the initiation of the neuroinflammatory 
response. 
6.1.1.2 IL-6 
The prevalence of IL-6 producing T lymphocytes and the intracellular IL-6 
levels were comparable in the two HIE groups, no significant difference was present. 
Interestingly, in both of the HIE groups CD4+ lymphocytes expressed the highest level 
of IL-6 at 24 h, indicated by the peak of the MFI of IL-6 at this time point. IL-6 
production decreased afterwards, suggesting that IL-6 may also play an important role 
in the initial phase of the neuroinflammatory response (Figure 11).  
We found a difference in the plasma level of IL-6, which was higher in severe 
HIE at 1 wk than in moderate HIE. We found a decrease in plasma IL-6 levels in the 






Figure 11. Alterations in the intracellular IL-6 level of CD4+ T cells and plasma IL-
6 levels during the first month of life within the moderate and severe HIE groups. 
Intracellular level is shown by the MFI of IL-1β. Plasma IL-1β level is shown in pg/ml. 
Moderate HIE (n = 17), severe HIE (n = 11). Horizontal line: median, box: 
interquartile range, whisker: range. p ≤ 0.05 a vs 6 h, b vs 24 h, c vs 72 h, d vs 1 wk 
(all within the same group), * = vs moderate at the same time point. 
6.1.1.3 IL-17 
The prevalence of IL17-producing CD4+ T cells, known as Th17 cells 
increased by 24 h compared to 6 hours of life and remained elevated during the first 
month of life. (Figure 12). At 1 wk this value was significantly higher in severe HIE 
(Table 6). Intracellular IL-17 production (indicated by the MFI of IL-17) was also 
higher in the severe group compared with the moderate group at 72 h in CD4+ 
lymphocytes. (Table 6).  
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The prevalence of CD8+ IL17+ T lymphocytes was on the other hand higher 
in moderate, than in severe HIE at 6 h (Table 6). Within the moderate group, IL-17 
production (indicated by the MFI of IL-17) peaked at 72 h and decreased by 1 mo in 
CD8+ cells. However, at 24 h, the intracellular IL-17 level of CD8+ cells was 
somewhat higher in severe HIE (Figure 12) No differences could be detected between 
the two study groups in the plasma levels of IL-17. 
 
Figure 12. Differences in the prevalence of IL-17 producing CD4+ lymphocytes and 
intracellular IL-17 production of CD8+ lymphocytes during the first mo of life in 
moderate and severe HIE. Cell prevalence data is shown in the percentage of the 
parent population. Intracellular level is shown by the MFI of IL-1β. Moderate HIE (n 
= 17), severe HIE (n = 11). Horizontal line: median, box: interquartile range, whisker: 
range. p ≤ 0.05 a vs 6 h, b vs 24 h, c vs 72 h (all within the same group), * = vs 
moderate at the same time point. 
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Figure 13. Differences in the prevalence of CD49d producing TNF-α+ CD4+ 
lymphocytes and intracellular TNF-α production of CD4+ lymphocytes during the 
first mo of life in moderate and severe HIE. Cell prevalence data is shown in the 
percentage of the parent population. Intracellular level is shown by the MFI of IL-1β. 
Moderate HIE (n = 17), severe HIE (n = 11). Horizontal line: median, box: 
interquartile range, whisker: range. p ≤ 0.05 a vs 6 h (within the same group), * = vs 
moderate at the same time point.  
The TNF-α production of CD4+ lymphocytes (MFI of TNF-α) was increased 
at all time points compared to 6 h in both HIE groups. By 1 mo, the MFI of TNF-α in 
CD4+ cells was higher in the severe group than in the moderate, suggesting the 
presence of an ongoing inflammatory response, which could contribute to the long-
term consequences of perinatal asphyxia. Plasma levels of TNF-α did not differ.  
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The prevalence of CD49d-expressing CD4+ TNF-α+ lymphocytes, which are 
prone to enter the CNS is lower in severe HIE at 6 h compared to moderate HIE and 
also compared to later time points, indicating increased extravasation. The prevalence 
of CD49d-expressing CD4+ TNF-α+ cells then increased and became higher in severe 
HIE than in moderate HIE by 72, which could be a result of increased CD49d 
production (Table 6 and Figure 13). 
6.1.1.5 OTHER PRO-INFLAMMATORY CYTOKINES 
The MFI of IFN-γ in CD4+ cells was elevated in severe HIE compared to 
moderate HIE at 72 h. Plasma G-CSF levels were higher in the severe group than in 
the moderate group at 24 h and 1 wk (Table 6).In moderate HIE, plasma G-CSF levels 
showed a decrease by 1 wk and remained low during the rest of the first month of life. 
Plasma MCP-1 levels within the moderate group were elevated at 24 h, 72 h and 1 wk 





6.1.2 ANTI-INFLAMMATORY FACTORS 
Table 7.  Differences in anti-inflammatory factors between moderate and severe HIE 
groups. The prevalence of T cells expressing certain cytokines are shown as the 
percentage of the parent population. Plasma cytokine levels are shown in pg/ml. The 
concentration of the factors measured by HPLC is shown in µM. Data are expressed 
as median and interquartile range. Only significant alterations are shown, p ≤ 0.05 in 
all cases. 
 
Time Moderate HIE 
(n = 17) 
Severe HIE 
(n = 11) 
Cell prevalence data (% of parent population) 
CD4+ Foxp3+/CD4+ 24 h 2.35 (1.96-3.13) % 3.02 (2.60-4.13) % 
Plasma cytokines (pg/ml) 
IL-5 72 h 1.37 (0.00-4.69) 0.20 (0.00-0.46) 
IL-13 72 h 2.35 (2.01-3.67) 1.70 (1.40-2.56) 
HPLC results (µM) 






In the moderate group, the prevalence of CD49d-expressing CD4+ TGF-β+ 
cells increased after 72 h and remained elevated until the end of the first month of life. 
This indicates a greater potential for TGF-β producing cells to enter the CNS in from 
1 wk onwards moderate HIE. CD4+ cells also expressed higher levels of TGF-β from 
24 h onwards in the moderate group. Although similar tendencies were present in the 
severe group alterations did not reach significant levels (Figure 14). 
 
Figure 14. Differences in the prevalence of CD49d producing TGF-β+ CD4+ 
lymphocytes and intracellular TGF-β production of CD4+ lymphocytes during the 
first month of life in moderate HIE. Cell prevalence data is shown in the percentage 
of the parent population. Intracellular level is shown by the MFI of IL-1β. Moderate 
HIE (n = 17). Horizontal line: median, box: interquartile range, whisker: range. p ≤ 
0.05 a vs 6 h, b vs 24 h, c vs 72 h (all within the same group). 
6.1.2.2 TREGS 
The prevalence of Tregs was somewhat higher in severe HIE at 24 h, which 
might be a result of a compensatory mechanism, however, the biological significance 
of this increase is difficult to determine (Table 7) (284). 
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6.1.2.3 OTHER ANTI-INFLAMMATORY CYTOKINES 
In the moderate group, plasma IL-10 levels decreased by 1 mo and were lower 
than at 6 and 24 h. In the severe group, plasma IL-13 levels decreased by 72 h and 
were lower than at 6 and 24 h in the following timepoints (Figure 15). Plasma IL-13 
and IL-5 levels were higher in the moderate than in the severe group at 72 h (Table 7). 
 
Figure 15. Alterations of the plasma levels of anti-inflammatory cytokines in 
moderate and severe HIE. Plasma cytokine levels are shown in pg/mL. Moderate HIE 
(n = 17), severe HIE (n=11). Horizontal line: median, box: interquartile range, 
whisker: range. p ≤ 0.05 a vs 6 h, b vs 24 h, c vs 72 h (all within the same group). 
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6.1.2.4 THE KYNURENINE SYSTEM 
The plasma levels of KYN were higher in moderate HIE at 1 mo than in severe 
HIE (Table 7). The components of the kynurenine system otherwise showed similar 
alterations in time within the two HIE groups. TRP levels showed a gradual increase 
in both groups by the end of the first month of life. Parallelly, plasma KYN and KYNA 
levels showed a gradual decline until 1 mo. In line with the above alterations, the 
enzymatic activity of IDO, indicated by the ratio of KYN and TRP (K/T ratio) also 
showed a decline by the end of the first month after the perinatal HI injury (Figure 16). 
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Figure 16. Alterations in the components of the kynurenine pathway in time in 
moderate and severe HIE.  Values are shown in µM. Horizontal line: median, box: 
interquartile range, whisker: range. KYN – kynurenine, KYNA – kynurenic acid, TRP 
– tryptophan, K/T – kynurenine/tryptophan ratio. p ≤ 0.05 a vs 6 h, b vs 24 h, c vs 72 
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6.1.3 ROC ANALYSIS 
We also assessed each parameter’s value in distinguishing between moderate 
and severe HIE by ROC analysis. We found, that all significant results are connected 
to IL-1β. By assessing the prevalence of IL-1β-producing CD4+ T cells at 6 h (p = 
0.018, ROC AUC = 0.784) and the CD49d expression of the above cells at 6 h (p = 
0.027, ROC AUC = 0.767) we could differentiate between moderate and severe insult 
with a reasonable sensitivity and specificity (Figure 17) early on (284). 
 
 
Figure 17. Receiver operator curve (ROC) analysis to differentiate between 
moderate and severe HIE based on the prevalence of A) CD4+ IL-1β+ T cells and 
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6.2 COMPARISONS BETWEEN HIE AND NAIS  
6.2.1 CYTOKINE PRODUCTION OF T LYMPHOCYTES 
Table 8. Differences in the intracellular levels of pro-inflammatory cytokines and 
the prevalence of T cells expressing pro-inflammatory cytokines between HIE and 
NAIS. The prevalence of T cells expressing certain cytokines is shown as the 
percentage of the parent population. The intracellular levels of each cytokine are 
shown by the mean fluorescence intensity (MFI) of each cytokine in arbitrary unit. 
Data are expressed as median and interquartile range. We are showing the study 
populations between which significant differences are present in bold. p≤ 0.05 * = vs 
moderate, ** = vs severe. 
 Time Moderate 
HIE 
(n = 17) 
Severe HIE 
(n = 11) 
NAIS 
(n = 4) 
Cell prevalence data (% of parent population) 










**, p ≤ 0.05 










Intracellular cytokine levels - MFI data (arbitrary unit) 







*, p ≤ 0.01 







**, p ≤ 0.05 







*, p ≤ 0.05 
**, p ≤ 0.05 







*, p ≤ 0.05 
**, p ≤ 0.05 
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6.2.1.1 PRO-INFLAMMATORY CYTOKINES 
Similar to our observations in HIE, CD4+ T lymphocytes produced the highest 
level of IL-1β at 6 hours in NAIS as well. This was indicted by the elevated MFI value 
of IL-1β, which decreased significantly by 24 hours. We found no difference between 
NAIS and HIE groups in the intracellular production of IL-1β (Figure 18). 
 
Figure 18. Alterations in the intracellular IL-1β level of CD4+ lymphocytes, during 
the first mo of life in moderate, severe HIE and NAIS. Intracellular level is shown 
by the MFI of IL-1β. Moderate HIE (n = 17), severe HIE (n = 11), NAIS (n = 4). 
Horizontal line: median, box: interquartile range, whisker: range. p ≤ 0.05 a vs 6 h 
(within the same group). 
 
The MFI of IL-6 in CD8+ cells at 72 h was lower in NAIS than in severe HIE. 
However, by 1 mo the MFI of IL-6 in CD8+ cells decreased in both HIE groups but 
became higher in NAIS (Table 8). 
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At 6 h the prevalence of CD8+ lymphocytes producing IL-17 was higher in 
NAIS than in severe HIE and CD8 cells also expressed higher levels of IL-17 at 6 h in 
NAIS than moderate HIE (Table 8).   
In NAIS, CD4+ lymphocytes expressed the highest level of IFN-γ at 24 h. 
Intracellular IFN-γ level decreased significantly by 72 h, by when it became lower in 
NAIS than in either HIE groups. The prevalence of IFN-γ+ CD4 cells did not differ 
between the study populations (Table 8 and Figure 19). 
 
Figure 19. Alterations in the intracellular IFN-γ level of CD4+ lymphocytes, during 
the first month of life in moderate, severe HIE and NAIS. Intracellular level is shown 
by the MFI of IFN-γ. Moderate HIE (n = 17), severe HIE (n = 11), NAIS (n = 4). 
Horizontal line: median, box: interquartile range, whisker: range. p ≤ 0.05 a vs 6 h, b 
vs 24 h, c vs 72 h (all within the same group), * = vs moderate at the same time point, 
** = vs severe at the same time point. 
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6.2.1.2 ANTI-INFLAMMATORY CYTOKINES 
The prevalence of IL-10+ CD8 lymphocytes was lower in NAIS than in the 
severe HIE at 6 h and 72. Although the prevalence of IL-10+ CD8 lymphocytes 
remained consistently lower in NAIS, the difference was not significant level at the 24 
h time point. On the other hand, the prevalence of IL-10+ CD4 cells was higher at 24 
h in NAIS than in moderate HIE (Table 9) (233).  
Table 9. Prevalence of T lymphocytes producing anti-inflammatory cytokines  
The prevalence of T cells expressing anti-inflammatory cytokines are shown as the 
percentage of the parent population. Data are expressed as median and interquartile 
range; p ≤ 0.05 * = vs moderate HIE, ** = vs severe HIE. Data, where significant 
differences were present compared to NAIS are shown in bold. 
 
  Moderate HIE 
(n = 17) 
Severe HIE 
(n = 11) 
NAIS 
(n = 4) 
Cell prevalence data (% of parent population) 







**, p ≤ 0.01 







*, p ≤ 0.05 







**, p ≤ 0.05 
CD4+ TGF-β+ CD49d+ 
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At 1 wk the prevalence of CD49d-expressing TGF-β+ CD4 lymphocytes, 
which are prone to enter the CNS was elevated in NAIS compared to both HIE groups, 
and all other time points within the NAIS group (Figure 20). By 1 mo of age however, 
the prevalence of TGF-β+ CD4 cells became lower in NAIS than in HIE (Table 9). 
Figure 20. Alterations in the prevalence of cells expressing CD49d within the CD4+ 
TGF-β+ population during the first mo of life within the moderate, severe HIE and 
NAIS. Moderate HIE (n = 17), severe HIE (n = 11), NAIS (n = 4). Horizontal line: 
median, box: interquartile range, whisker: range. p ≤ 0.05 a vs 6 h, b vs 24 h, c vs 72 
h (all within the same group); * vs moderate HIE at the same time point, ** vs severe 
HIE at the same time point. 
6.2.2 PLASMA CYTOKINES 
Our results indicate a marked inflammatory response in NAIS at 72 hours, 
characterized by the elevated plasma levels of several cytokines, i.e. IL-5, IL-17 and 
MCP-1 compared to HIE (Table 10). Plasma MCP-1 level at 72 h was higher than at 6 
h than at all other time points within the NAIS group (Figure 21). By 1 mo however, 
inflammatory response appears to decrease in NAIS, as plasma levels of IL-4, IL-12 
and IL-17 are lower compared to HIE groups (Table 10). The level of IL-4 was lower 
at 1 mo than at 72 h within the NAIS group (Figure 21) (233). Plasma IL-12 and IL-
17 levels showed a similar decreasing tendency at 1 mo, however this difference was 
not significant, probably due to the fact, that the number of cases was very low.  
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Table 10. The differences in plasma cytokine levels between moderate, severe HIE 
and NAIS. The plasma levels of cytokines are shown at different time points in pg/mL. 
Data are expressed as median and interquartile range; p≤ 0,05; *= vs moderate at the 
same time point, ** = vs severe at the same time point. The data, where significant 
differences were present compared to NAIS are shown in bold. 
 Time Moderate HIE 
(n = 17) 
Severe HIE 
(n = 11) 
NAIS 
(n = 4) 
Plasma cytokines (pg/ml) 
IL-5 72 h 
1.37 (0.00-4.69) 0.20 (0.00-0.46) 3.42 (1.42-6.35) 
**, p ≤ 0.01 






*, p ≤ 0.05 
**, p ≤ 0.05 






*, p ≤ 0.05 






*, p ≤ 0.05 







*, p ≤ 0.05 







*, p ≤ 0.05 
**, p ≤ 0.01 
 
The plasma levels of IL-1β, IL-2, IL-6, IL-7, IL8, IL-10, IL-13, IFN-γ, TNF-
α, TGF-β, G-CSF, GM-CSF, MIP-1β and VCAM showed no alteration is NAIS 







Figure 21. Alterations of the plasma cytokine levels in the first month of life in NAIS. 
Plasma cytokine levels are shown in pg/mL. NAIS (n=4). Horizontal line: median. 
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7.1 COMPARISONS BETWEEN MODERATE AND SEVERE HIE 
The developing brain of a neonate responds very differently to HI injury than 
the adult brain. Although humans are capable of withstanding far longer periods of 
hypoxemia during the fetal period of life, and the neonatal brain has a substantial 
neuroplasticity, HI injury during the perinatal period is still much more likely to lead 
to severe brain damage and life-long disability. This is due to the unique vulnerabilities 
of the immature brain hypoxia-ischemia (2). Evidence indicates, that the cytokine 
network plays an essential role in the normal development of the CNS (463-465). As 
a consequence, the developing brain is particularly susceptible to the changes of the 
cytokine network. In addition, the cytokine network plays a central role in the 
neuroinflammatory response which follow HI brain injury (393). Therefore, the 
alterations of the cytokine network following HI brain injury represents an area of 
intensive research.  
The neuroinflammatory response results in complex changes in the cytokine 
network, which in certain cases lead to moderate HIE and good neurodevelopmental 
outcome, while in other cases result in severe HIE and poor outcome such as death or 
severe disability. We therefore aimed to understand the key features of 
neuroinflammation in moderate and severe HIE, especially focusing on the alterations 
of the adaptive immune system. Previous data mainly presented the alterations of 
plasma cytokine levels, which could provide a global overview of the immune 
response but gives no information about the characteristic changes of different immune 
cells. Therefore, our primary aim was to characterize the prevalence and cytokine 
production of T cells, however, we also measured plasma cytokine levels in order to 




7.1.1 PRO-INFLAMMATORY CYTOKINES 
7.1.1.1 IL-1β 
IL-1β is one of the most important pro-inflammatory cytokines, which appears 
to influence the severity of the neuroinflammatory response following HI brain injury 
in neonates (161). As previously detailed, there is surmounting evidence supporting 
the central role of IL-1β in the exacerbation of neuroinflammation, and consequently 
poor neurological outcome (see introduction). The detrimental consequences of 
elevated IL-1β production are further supported by data from human in vivo studies. 
In a study by Aly et al. the CSF level of IL-1β at 24 h of life was the best predictor of 
poor neurological outcome at 6 and 12 months after HI injury. They found a high CSF 
to plasma ratio of IL-1β, based on which they suggested, that local IL-1β production 
in the CNS is especially relevant. They concluded, that IL-1β appears to play a crucial 
role in the exacerbation of HI brain injury and is a marker of severe HIE (354).  
In our current study, we focused on the intracellular cytokine production of T 
lymphocytes and also measured plasma cytokine levels to observe correlations 
between the two. The capacity of T cells to produce IL-1β has only recently been 
identified and there is still much to understand about the functional relevance of this 
finding (389). However, we observed significant IL-1β production in T lymphocytes 
after perinatal HI brain injury, which was more pronounced in severe HIE in the early 
phase. Both the prevalence and the extravasation of IL-1β producing CD4+ T cells was 
higher in severe HIE than in moderate HIE at 6 h. Based on our ROC analysis, these 
data could be useful in differentiating between moderate and severe HIE at an early 
stage (up to 6 h after birth). IL-1β-producing CD4+ T lymphocytes appear to play an 
important role in the initial phase of neuroinflammation, as intracellular IL-1β levels 
were the highest at 6 h in both groups and were comparably lower at later time points. 
Plasma IL-1β levels also followed similar tendencies. Our data is in line with previous 
studies suggesting that enhanced IL-1β production could contribute to aggravated 
neuronal injury. However, as intracellular concentrations of IL-1β gradually decrease 
in both HIE groups after 6 h, it cannot be ruled out, that a certain level of initial increase 
could be a physiological necessity enabling the reparative processes.  
There is much data from animal models demonstrating the therapeutic benefits 
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of peripherally administered IL-1 receptor antagonistic agents following perinatal HI 
brain injury (466). IL-1 receptor antagonistic agents are in clinical use in several 
autoimmune disorders, and the possibility of IL-1β inhibition opens an intriguing 
novel area of research.  
Overall, our results suggest that IL-1β may play an important role in 
exacerbating tissue damage in the early phase of neuroinflammation after perinatal HI 
brain injury. Based on the prevalence and extravasation of IL-1β producing CD4+ T 
cells at 6 h, the severity of HIE can be predicted early on. Although it cannot be ruled 
out that a certain level of initial increase in IL-1β production is necessary for the 
physiological reparative process, our data - in line with previous results - indicates, 
that excess IL-1β production correlates with more severe HI injury (284).  
7.1.1.2 IL-6  
Recent years’ research data suggests, that IL-6 might play a dual role in the 
neuroinflammatory process after HI brain injury, exacerbating the inflammation in the 
early phase, but exerting anti-inflammatory or even neurotrophic effects in the 
secondary and tertiary phases (161). Previous human in vivo studies showed an 
association between elevated CSF levels of IL-6 after perinatal asphyxia and poor 
neurological outcome, cerebral palsy and death (393, 419). Martin-Ancel et al. 
measured CSF IL-6 levels in infants with severe HIE at 12 and 72 h and found a 
marked decrease during this period, which supports the detrimental effects of IL-6 in 
the early phase. Several authors suggest that during neuroinflammation IL-6 is 
primarily produced intrathecally, indicated by the high CSF to plasma ratios (393). It 
is important to mention however, that the majority of these results were obtained before 
therapeutic hypothermia was introduced, one of the most important effects of which is 
the rapid suppression of early cytokine response. In a previous study, Roka et al. 
demonstrated, that early IL-6 production (at 6 h) is suppressed by therapeutic 
hypothermia (246).  
In the current study we only found a difference between moderate and severe 
HIE in the plasma level of IL-6 at 1 wk of age, where it was higher in the severe group. 
By 1 mo, plasma IL-6 levels decreased in moderate HIE, but not in severe HIE. In T 
cells, we found no differences between the two study groups in intracellular IL-6 levels 
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or the prevalence of IL-6+ cells. It is interesting to note however, that the intracellular 
level of IL-6 in CD4+ T cells peaked at 24 hours in both patient groups and declined 
later, supporting the role of IL-6 in the acute phase. However, the fact that we found 
no alterations in the IL-6 production of peripheral T cells suggests, that the local 
production of IL-6 could be more relevant. Another possible explanation is that 
hypothermia effectively suppresses the IL-6 production of T cells (284).  
7.1.1.3 IL-17 
IL-17 is an important pro-inflammatory cytokine primarily produced by a pro-
inflammatory subset of T cells, Th17 cells. IL-17 has been shown to increase delayed 
neuronal damage in the chronic phase of neuroinflammation (402). In the current 
study, we found a continuous elevation in the prevalence of IL-17 expressing CD4+ T 
cells (Th17 cells) in severe HIE from 24 h until the end of the observation period. This 
increase was not present in moderate HIE. At 1 wk this difference between the study 
populations was significant, which supports the role of Th17 cells in the delayed 
progression of HI injury. CD4+ T lymphocytes also produced higher amounts of IL-
17 in the severe group at 72 h than the moderate group. CD8+ T cells also produced 
higher amounts of IL-17 in severe HIE at 24 h. This delayed increase in the prevalence 
and cytokine production of  Th17 cells could indicate their role in maintaining the 
chronic, latent neuroinflammation, which could influence functional regeneration 
unfavorably (284).  
7.1.1.4 TNF-α 
The amount of data supporting the deleterious effects of TNF-α during 
neuroinflammation is compelling (see introduction). Although TNF-α is capable of 
promoting cell survival in certain immunological contexts, it appears, that the receptor 
constitution of CNS cells during neuroinflammation is unfavorable. TNF-α has been 
associated with reduced oligodendrocyte survival and myelination, worse neurological 
outcome and higher incidence of cerebral palsy in term infants with HIE (420, 405, 
421, 161).  
In this study, we found a delayed increase in the TNF-α production of CD4+ T 
cells from 24 hours of life until the end of our observation period in both study group. 
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At 1 mo, the intracellular level of TNF-α in CD4+ T cells was higher in the severe 
group than in the moderate group, which suggests, that a sustained elevation in TNF-
α production could be an important aspect of the chronic, latent neuroinflammation, 
contributing to the long-term consequences of HIE. In a study enrolling 7-year-old 
children with cerebral palsy, who were born preterm, both plasma TNF-α levels and 
TNF-α production of PBMCs upon stimulation was elevated compared to age-matched 
children, who were also born prematurely but had normal neurodevelopmental 
outcome. This alteration could indicate, that an enhanced pro-inflammatory response 
could remain even seven years after the initial phase of the neuroinflammatory 
response and that TNF-α could play an important role in this prolonged immune 
activation (118, 467).  
Another interesting observation was, that at 6 hours the prevalence of TNF-α 
producing CD4+ T cells prone to enter the CNS (CD49d+ CD4+ TNF-α+ cells) was 
lower in severe HIE than at all other time points and also compared to moderate HIE. 
We interpreted this as a result of increased extravasation, suggesting that TNF-α 
producing CD4+ cells could also play a role in the early phase of the 
neuroinflammatory response. From 24 hours onward however, we found an increase 
in CD49d-expression of TNF-α+ CD4+ T cells in severe HIE, which at 72 h reached a 
significantly higher level than in moderate HIE. This could mean increased CD49d 
production in severe HIE in the chronic phase of neuroinflammation, which could lead 
to an enhanced capacity of CD4+ TNF-α+ cells to enter the CNS. This hypothesis, that 
the delayed increase in CD49d expression reflects elevated production is supported by 
the observations of Rothhammer et al., who showed that in mice naïve T cells (CD4+ 
CD44- Foxp3-) require approximately 3 days in Th1 promoting milieu to differentiate 
into encephalitogenic T cells, which express high levels of CD49d (468). This timeline 
could account for our observations and explain the initial decrease in the prevalence 
of CD49d+ TNF-α+ CD4+ T cells as the consequence of increased extravasation, 
decreasing the circulating pool of cells and the delayed elevation in the prevalence of 
these cells as a result of increased differentiation and CD49d production leading to an 
increased pool of circulating cells (284). Overall, our results suggest that TNF-α-
producing CD4+ T cells play an important role during neuroinflammation, especially 
in the maintenance of a chronic ongoing inflammatory response.   
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7.1.2 ANTI-INFLAMMATORY FACTORS 
We aimed to gain a comprehensive overview of the anti-inflammatory 
components of the adaptive immune system, and therefore measured intracellular and 
plasma TGF-β levels, the prevalence of Treg cells and the components of the 
kynurenine (KYN) pathway.  
TGF-β is one of the most important immunoregulatory cytokines, inhibiting 
the function of pro-inflammatory cells, promoting Treg function and establishing an 
anti-inflammatory milieu (428-434). In addition to its immunological function, TGF-
β is essential for the development, repair and survival of neurons (355). There is 
substantial evidence indicating that TGF-β exerts neuroprotective effects after HI brain 
injury, possibly by attenuating inflammation, protecting from excitotoxicity and 
apoptosis and promoting neuroregeneration (441). After HI injury, factors associated 
with reparative processes, including TGF-β have been shown to be expressed later than 
pro-inflammatory cytokines (355). In our study, we found elevated intracellular TGF-
β levels in CD4+ T lymphocytes in moderate HIE from 24 h onwards. In the severe 
group, the elevation did not reach a significant level. TGF-β producing CD4+ T cells 
also showed a higher capacity to enter the CNS (indicated by the increased prevalence 
of CD49d+ cells) at 1 wk and 1 mo compared to 72 h in the moderate group, which 
was also not present in severe HIE. This delayed increase in TGF-β production and 
increased capacity for extravasation in the chronic phase of the neuroinflammation 
could play a role in attenuating the inflammatory response and promoting 
neuroregeneration in moderate HIE. The lack of this immunoregulatory effect could 
be an important component of the more aggravated neuroinflammatory process in 
severe HIE. The prevalence of Treg cells did not differ considerably between the two 
study groups, we only observed a moderately higher prevalence of Treg cells in severe 
HIE at 24 h, which could be a part of a compensatory mechanism.  
The kynurenine system exerts many immunoregulatory functions and is an 
important link in neuro-immune interactions. It appears to be involved in the 
pathophysiology of a wide array of neurological disorders, however, no data has been 
published from perinatal HI injury previously (455). In the current study, we observed 
a significant increase in TRP levels in both groups by 1 mo of life. In line with this, 
the level of TRP catabolite KYN and further catabolite KYNA decreased in both 
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groups from 1 wk onwards. This indicates an enhanced IDO enzymatic activity during 
the first wk (calculated from the ratio of KYN to TRP) which declines by 1 mo of age 
in both HIE groups. However, at 1 mo of age, KYN levels were higher in moderate 
HIE than in severe HIE, which could be a sign of augmented anti-inflammatory 
processes in moderate HIE. Overall, following perinatal HI brain injury, an elevated 
IDO activity and TRP catabolism is present in the early postnatal period (until 1 wk of 
age) in both moderate and severe HIE. This could be part of a physiological 
immunoregulatory process, suppressing the inflammatory response to hypoxia-
ischemia. However, by the end first mo after perinatal HI injury the significance of this 




7.2 COMPARISONS BETWEEN HIE AND NAIS  
As previously described, the inflammatory pathway appears to play an 
important role in the pathomechanism of NAIS. On the one hand, it appears that an 
inflammatory pre-conditioning could be one of the cornerstones of the development of 
NAIS (214), on the other hand, ischemic brain injury triggers a neuroinflammatory 
response, which causes the brain lesion to develop over an extended period of time. 
This is a common feature of HIE and NAIS and is often the time when neonates are 
admitted to the intensive care unit. There is evidence supporting the role of T 
lymphocytes in this process (232), however, hardly any data is available on the 
alterations of the adaptive immune responses in NAIS (See pathophysiology of NAIS). 
T lymphocytes are key members of the adaptive immune system, exerting their effects 
largely via the cytokine network. Therefore, describing the alterations of the cytokine 
production of T lymphocytes is an important aspect of understanding the role of the 
adaptive immune system in the development of NAIS. Plasma cytokine levels could 
also provide further insight into the immune pathology. By measuring the same 
parameters over the entire first month of life, it could be possible to map the dynamic 
changes occurring in the peripheral blood during the inflammatory process following 
NAIS. Although HIE and NAIS often presents with similar clinical signs and overlap, 
there is more and more evidence indicating, that there are also fundamental differences 
between these two conditions and it would be important to differentiate between them 
early on which is not always possible based on clinical presentation.  
7.2.1 PRO-INFLAMMATORY CYTOKINES 
The intracellular IL-1β production is comparable between HIE and NAIS. IL-
1β also appears to play a role in the early events of the neuroinflammatory process 
after NAIS, indicated by the initial elevation in IL-1β production, which decreases by 
24 h of age. 
The intracellular IL-6 production of CD8+ lymphocytes is different in NAIS 
compared to HIE. At 72 h the intracellular IL-6 level of CD8+ cells is higher in severe 
HIE than in NAIS. However, at 1 mo whereas the IL-6 level in CD8+ cells remains 
elevated in NAIS patients, it decreases in both HIE groups. This finding is intriguing 
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in light of the emerging evidence of the dual role of IL-6 following HI injury, exerting 
mainly pro-inflammatory effects in the early phase and anti-inflammatory effects in 
the chronic phase of neuroinflammation during the regenerative processes (161). 
Whereas we observed no difference between the two HIE groups in IL-6 production, 
the elevated IL-6 production at 72 h in severe HIE compared to NAIS could reflect an 
aggravated inflammatory process in severe HIE. On the other hand, the sustained 
elevation in NAIS during the first month of life could be part of the chronic 
neuroregenerative process. This is in line with literary data from pediatric stroke cases, 
where plasma IL-6 levels were still elevated 6 months after AIS (236).  
IL-17 is the characteristic cytokine produced by Th17 (CD4+), Tc17 (CD8+) 
cells and γδ-T cells. IL-17 producing cells have been found to be associated with acute 
ischemic stroke (AIS) in adults. One week after AIS the plasma level of IL-17 and the 
prevalence of circulating Th17 cells was elevated in adults and showed a decrease by 
1 month (469). Th17 cells are also suspected to play a role in the development of HI 
injury. Yang et al. found a significant influx of Th17 cells into the brain tissue, if HIE 
occurred after LPS sensitization in rats or following a history of maternal 
chorioamnionitis in human neonates (403). At 6 h, there was a higher prevalence of 
IL-17 producing CD8+ T lymphocytes (Tc17 cells) in NAIS than in severe HIE, and 
CD8+ cells also produced higher amounts of IL-17 in NAIS than in moderate HIE. 
Tc17 cells have been shown to play a role in a variety of inflammatory diseases (401). 
For instance, in active brain lesions of multiple sclerosis patients, elevated IL-17 
expression was present in both CD4+ and CD8+ T cells (470). We also found a higher 
plasma levels of IL-17 in the secondary phase of neuroinflammation (at 72h) in NAIS 
than in HIE. However, by 1 mo, the plasma level of IL-17 decreased in NAIS, while it 
remained elevated in HIE. As NAIS is suspected to develop on the base of in-utero 
inflammatory pre-conditioning, it is possible, that IL-17 producing T cells could play 
a role in the immune pathology.  
In NAIS intracellular IFN-γ production of CD4+ T cells peaked at 24 h and 
decreased by 72 h, when it became lower than in either HIE groups. Intracellular IFN-
γ levels of CD4+ T cells remained comparably lower in the later time points. IFN-γ is 
a characteristic Th1 cytokine, which is produced in the highest amounts by these cells. 
It is therefore possible, that an enhanced Th1 response is present in HIE compared to 
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NAIS during the secondary phase of neuroinflammation.  
MCP-1 plays a central role in the activation of monocytes and is potent 
chemoattractant for them. MCP-1 is also suspected to play a role in the development 
of NAIS. In one murine model of chorioamnionitis-associated perinatal stroke, the 
level of MCP-1 was elevated in HI injury only if in-utero LPS sensitization was present 
previously (214). In our study, the level of MCP-1 was elevated in NAIS at 72 h both 
compared to the starting 6 h value and compared to moderate HIE, which could support 
the association between of in-utero inflammation and NAIS. 
Overall it appears that CD8+ T cells show a slightly altered cytokine profile, 
with a more prominent pro-inflammatory response in NAIS. IL-17 producing cells 
could also be involved in the pathomechanism of NAIS, however further investigations 
are necessary to verify these findings and determine their relevance (233). Plasma 
cytokine levels also indicate a difference between NAIS and HIE. We found signs of 
an enhanced inflammatory response at 72 h in NAIS compared to HIE, when the level 
of IL-17 and MCP-1 were elevated in NAIS.  
7.2.2 ANTI-INFLAMMATORY CYTOKINES 
The anti-inflammatory pathways also show some specific characteristics in 
NAIS. IL-10 is a characteristic cytokine produced by regulatory T cells, which exerts 
a wide array of anti-inflammatory effects and has been shown to be neuroprotective 
after HI injury (426, 406). Trandem et al. were however recently also able to 
demonstrate in a murine model of virus encephalitis, that CD8+ T lymphocytes (CTLs) 
are also capable of producing significant amounts of IL-10 at the peak of their 
activation. They concluded, that CTL-derived IL-10 is most likely to play an important 
autoregulatory role when the activation of these cells reaches a certain level, 
preventing local tissue destruction. The expression IL-10 decreased rapidly after 1 wk 
in CTLs in this experiment, whereas CD4+ T cells expressed IL-10 for a much longer 
time, up to at least 42 days (471). In our current study we found a higher prevalence 
of IL-10 expressing CD8+ lymphocytes in severe HIE than in NAIS during the first 
72 hours of life. The prevalence of IL-10 expressing CTLs was also slightly higher in 
moderate HIE than in NAIS, but this did not reach a significant level. On the other 
hand, the IL-10 production of CD4+ lymphocytes was higher in NAIS than in 
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moderate HIE at 24 h.  
One explanation for this finding could be, that in severe HIE, the more global 
and aggravated inflammatory response evokes a higher level of CTL-activation as 
well, which in return produce more IL-10. Another, more plausible explanation could 
be, that there is a difference in the onset of the two disorders. Whereas evidence 
supports, that the majority of events causing global asphyxia occur during or around 
the birth, NAIS is likely to be preceded by a longer period of ongoing inflammation. 
In this case, the explanation could be, that the IL-10 production of CD8+ T cells 
decreases in NAIS by the time of birth. This would also give a reasonable explanation 
to the elevated prevalence of IL-10 producing CD4+ T cells, since Th cells are known 
to produce IL-10 for a much longer time. Altogether the IL-10 production of T cell 
subsets also appears to be different in NAIS and HIE and could also suggest an earlier 
onset of inflammation in NAIS.  
Another intriguing finding is that the prevalence of TGF-β-producing Th cells 
prone to enter the CNS (CD49d-expressing TGF-β+ CD4+ T cells) was significantly 
higher at 1 wk in NAIS compared to 6 h, and also compared to both HIE groups. The 
prevalence of these cells shows an increase within the moderate HIE group after 72 h, 
but still reaches a significantly higher level in NAIS. TGF-β is the primary cytokine of 
Treg cells and is one of the most important neuroprotective cytokines, which also plays 
a role in neuroregeneration. Thus, it appears, that there is a marked peak in 
immunoregulatory cells entering the CNS 1 wk in NAIS. By 1 mo however, the 
prevalence of circulating TGF-β-producing Th cells decreases in NAIS and becomes 
lower compared to both HIE groups. This is in line with the alterations of the plasma 
cytokine levels, which also indicate a general attenuation of the inflammatory response 
by 1 mo in NAIS compared to HIE.  
Among the plasma cytokines, the level of IL-5 was in NAIS than in HIE. IL-5 
is a Th2 associated cytokine, the elevation of which could be part of a generally 
enhanced inflammatory response, which could also be a sign of the beginning of the 
reparative phase. By 1 mo we saw a general decrease in the plasma level of several 
cytokines, including Th2 associated cytokines such as IL-4 in NAIS compared to HIE. 
This indicates, that there is a general moderation of the inflammatory process in NAIS 
compared to HIE (233).   
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7.3 STUDY LIMITATIONS 
The main limitation of our study is the lack of a healthy control group. 
Although this would have provided further insight into the physiological adaptation of 
the immune system during the first month of life and into the alterations which are 
cause by HIE, due to the sophisticated study design and the high number of samplings, 
this could not have been carried out ethically in healthy neonates. Although the above-
mentioned data would be scientifically interesting, the real clinical relevance of such 
data is questionable. On the one hand, there are several studies providing such data 
from individual time points, on the other hand, the real clinical question is the factors 
which differentiate between a moderate and a severe insult. Therefore, we believe that 
our study is still able to provide relevant data, even if the comparisons are made 
between two patient populations. Another limitation is the lack of data from the local 
milieu from CSF or brain samples, however, the current clinical practice no longer 
warrants CSF sampling in HIE. A further limitation of the study is that five neonates 
in each study group had to be administered hydrocortisone as part of blood pressure 
support, the impact of which on their cytokine production cannot be ruled out. This 
question needs further investigation. 
Clearly, the main limitation regarding the comparisons made between HIE and 
NAIS is the very small number of cases. Therefore, these data must be considered as 
incentive for future, larger case-control studies. We observed a notable variability in 
certain plasma cytokine levels within this small group of patients, which could be due 
to the relative instability of plasma cytokines. It is possible, that with increasing the 
number of cases, this will decrease, however, plasma cytokine levels tend to show 
greater variability than intracellular levels. We see the value of these results in 
providing a base for future clinical research on differentiating factors between the two 
distinct etiologies (global hypoxic-ischemic encephalopathy and perinatal arterial 
ischemic stroke), which often overlap clinically. Since gaining a better understanding 
of the pathophysiology of NAIS is a primary focus in this field, and no such serial data 
have been previously published in humans, despite the small number of cases, these 
data could provide a novel insight into the immunological processes following NAIS 




In conclusion, the involvement of the cytokine network in the development of 
perinatal HI injury is supported by a rapidly expanding body of evidence. 
Understanding the alterations of this complex network of neuro-immune interactions 
are a key focus in current research, with special attention on prognostic markers and 
options for individualized therapy. Another important focus is understanding the 
tertiary, latent phase of neuroinflammation and its contribution to the development of 
HI injury, as this period could be especially important for intervention. 
With regards to the alterations of T lymphocytes in perinatal HIE, IL-1β and IL-6 
producing T lymphocytes appear to play a key role in the adaptive immune response 
during the early phase of neuroinflammation, whereas prolonged TNF-α-production 
of T cells could be an important component of the latent, chronic phase of 
neuroinflammation. The prevalence of Th17 cells was elevated in severe HIE from 24 
h onwards (compared to 6 h) and at 1 wk it was significantly higher than in moderate 
HIE, which suggests, that Th17 cells could also play a role in delayed progression of 
injury. Elevating TGF-β levels could be important in regulating the inflammatory 
response and initiating neuroregeneration (Table 11). By assessing the prevalence of 
peripheral IL-1β expressing CD4+ cells and the CD49d expression of these cells at 6 
h, it was possible to differentiate between moderate and severe HIE at an early stage 
(284). 
To conclude our findings in NAIS, our data indicate an enhanced inflammatory 
response at 72 h in NAIS compared to HIE, characterized by the elevation several 
cytokines (i. e. IL-5, IL-17, MCP-1). At 1 week there is a marked increase in the 
extravasation of TGF-β producing CD4+ T cells in NAIS both compared to the 6 h 
value and HIE, which could indicate an earlier initiation of the reparative process. It 
appears that the inflammatory response becomes attenuated by 1 month, which is 
indicated by the decrease in plasma cytokine levels (i. e. IL-4, IL-12, IL-17) and the 
prevalence of TGF-β producing CD4+ T cells. Differences in the levels of cytokines 
which have been shown to link systemic inflammatory response with 
neuroinflammation, such as IL-17 and MCP-1 were present in NAIS. These data 
appear to support the hypothesis of an ongoing in-utero inflammation prior to NAIS, 
but larger case-control studies are pivotal to interpret the value of these findings.  
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8.1 KEY FINDINGS 
1) IL-1β and IL-6 producing T lymphocytes appear to play an important role in 
the early phase of the adaptive immune response in perinatal HIE. 
2) TNF-α production is sustained during the first month of life in T cells and is 
higher in severe HIE, which could contribute to a worse outcome 
3) The elevated prevalence of Th17 lymphocytes in severe HIE could indicate 
the role of this subset in the delayed progression of HI brain injury 
4) Elevating TGF-β production and increased extravasation CD4+ T could play 
an important regulatory role in HIE by initiating the reparative processes 
5) The assessment of the prevalence and CD49d expression of IL-1β+ CD4+ 
cells at 6 h appears to be able to predict severity at an early stage in HIE 
6) In NAIS the inflammatory response is more enhanced at 72 h than in HIE, 
indicated by the higher level of several plasma cytokines (i. e. IL-5, IL-17, 
MCP-1). 
7) At 1 wk, there is a marked increase in the extravasation of TGF-β producing 
CD4+ T cells in NAIS both compared to the 6 h value and HIE, which could 
indicate an enhanced reparative process 
8) By 1 mo the inflammatory response is attenuated in NAIS, indicated by lower 
plasma cytokine levels and the lower prevalence of TGF-β producing CD4+ 





Table 11. Summary of the proposed effect of cytokines on the course of hypoxic 
ischemic encephalopathy following perinatal asphyxia 
Pro-inflammatory Anti-inflammatory 
Contribution to better outcome 
G-CSF  rapid decrease in moderate 
insult, higher plasma levels 
in severe insult 
TGF-β increased production and 
extravasation in moderate insult 
 IDO early compensatory role, up to 
 1 wk 
Contribution to worse outcome 
IL-1β higher initial prevalence 
and extravasation in severe 
insult 
Treg Unremarkable difference at 24 h, 
lack of regulatory effect 
IL-6 highest level at 24 h, higher 
plasma levels in severe 
HIE at 1 wk, decrease in 
moderate HIE by 1 mo 
  
IL-17 elevated prevalence in 
severe HIE up to 1 mo 
  
TNF-α elevated intracellular levels 








Perinatal asphyxia and following hypoxic-ischemic encephalopathy (HIE) is one 
of the leading causes of child mortality and long-term disability in the world. The 
perinatal period also carries the highest risk for acute ischemic stroke (NAIS) in the 
entire childhood, which is one of the leading causes of cerebral palsy. 
Neuroinflammation is one of the most important features of perinatal HI brain injury. 
The severity of the neuroinflammatory response plays a key role in determining the 
degree of damage and ultimately the outcome. Neuroinflammation may have dual 
aspects being a hindrance, but also necessary for the recovery of the CNS.  
In this study, our aims were to characterize the alterations of the intracellular 
cytokine production of T-lymphocytes and plasma cytokine levels during the first 
month of life in HIE and NAIS:  
We analysed data from 32 term neonates requiring moderate systemic 
hypothermia in a single-centre observational study. Blood samples were collected on 
five occasions, between 3-6 h of life, at 24 h, 72 h, 1 wk and 1 mo of life. Neonates 
were divided into a moderate (n = 17) and a severe (n = 11) group based on 
neuroradiological and aEEG characteristics. Four neonates were diagnosed with NAIS 
by MRI. Peripheral blood mononuclear cells were assessed with flow cytometry. 
Cytokine plasma levels were measured using Bioplex immunoassays. Components of 
the kynurenine pathway were assessed by HPLC. 
In HIE IL-1β and IL-6 appear to play a key role in the adaptive immune response 
during the early phase of neuroinflammation, whereas elevated prevalence of Th17 
cells and prolonged TNF-α-production of T cells could be important aspects of the 
latent, chronic phase of neuroinflammation. Based on ROC analysis, the assessment 
of the prevalence and extravasation of IL-1β-producing CD4+ lymphocytes could 
predict the severity of HIE at 6 h. Increasing TGF-β production of CD4+ T cells could 
indicate their role in regulating the inflammation and initiating the reparative 
processes. In NAIS the plasma levels of several cytokines were elevated at 72 h. At 1 
wk, the extravasation of TGF-β producing CD4+ T cells was higher in NAIS which 
suggests the initiation of the reparative process. The inflammatory response appears to 
become moderated by 1 mo in NAIS. In NAIS we observed changes in several 




A perinatális asphyxia és a következményes hypoxiás-ischaemiás 
encephalopathia (HIE) a gyermekkori mortalitás és a maradandó idegrendszeri 
károsodás vezető oka. A perinatális időszak kiemelt kockázatot hordoz neonatális 
artériás ischaemiás stroke (NAIS) szempontjából is, amely a cerebrális parézis egyik 
legfontosabb oka. A neuroinflammáció alapvető meghatározója mindkét kórképhez 
kötötten bekövetkező károsodásnak. A neuroinflammatorikus válasz lefolyása 
meghatározza a központi idegrendszer károsodásának a súlyosságát.  
A célkitűzésünk a T limfociták prevalenciájának és citokin-termelésének, 
valamint a citokinek plazmaszintjének a jellemzése volt HIE-t és NAIS-t követően.  
A vizsgálatunkba 32 érett újszülöttet vontunk be, akik megfeleltek a mérsékelt, 
teljes test-hipotermia terápiás kritériumrendszerének. Összesen 5 alkalommal vettünk 
perifériás vérmintát az újszülöttektől 6, 24 és 72 órával a születést követően, valamint 
egy hetes, illetve 1 hónapos korban. A mérsékelt (n = 17) és súlyos HIE (n = 11) 
csoportok az aEEG és MRI vizsgálatok eredményei alapján utólag kerültek 
kialakításra. Négy újszülött esetében az MRI vizsgálat elvégzését követően NAIS 
igazolódott. A perifériás mononukleáris sejteket áramlási citometriával vizsgáltuk. A 
citokinek plazma szintjének meghatározására Bioplex immunassay-t alkalmaztunk. A 
kinurenin útvonal komponenseinek a szintjét HPLC segítségével mértük.  
A vizsgálataink azt támasztják alá, hogy a HIE-hez kapcsolódó neuroinflammáció 
során az IL-1β és az IL-6 alapvető szerepet játszik az adaptív immunválaszban a korai 
fázisban. ROC analízis alapján az IL-1β-t termelő CD4+ limfociták prevalenciájának 
és extravazációjának vizsgálata révén már korai fázisban (6 óránál) elkülöníthető volt 
a két csoport. Ezzel szemben a Th17 sejtek emelkedett prevalenciája, valamint a CD4+ 
T sejtek tartósan emelkedett TNF-α termelése fontos elemei lehetnek a 
neuroinflammáció krónikus fázisának. A fokozatosan emelkedő TGF-β termelés révén 
a CD4+ T sejtek fontos regulátoros szerepet játszhatnak és hozzájárulhatnak a KIR 
regeneráció megindulásához. NAIS-ban 72 órás korban számos citokin plazmaszintje 
emelkedett volt. Egy hetes korban a TGF-β termelő CD4+ sejtek extravazációja 
magasabb volt NAIS-ban, amely a regenerációs folyamatok korábbi megindulását 
jelezheti. NAIS esetében több olyan citokin szintjében észleltünk változást, amelyek 
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